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A B S T R A C T
Background
The management of advanced oral cavity and oropharyngeal cancers is problematic and has traditionally relied on surgery and radio-
therapy, both of which are associated with substantial adverse effects. Radiotherapy has been in use since the 1950s and has traditionally
been given as single daily doses. This method of dividing up the total dose, or fractionation, has been modified over the years and a
variety of approaches have been developed with the aim of improving survival whilst maintaining acceptable toxicity.
Objectives
To determine which radiotherapy regimens for oral cavity and oropharyngeal cancers result in increased overall survival, disease free
survival, progression free survival and locoregional control.
Search methods
The following electronic databases were searched: the Cochrane Oral Health Group’s Trials Register (to 28 July 2010), CENTRAL
(The Cochrane Library 2010, Issue 3), MEDLINE via OVID (1950 to 28 July 2010) and EMBASE via OVID (1980 to 28 July 2010).
There were no restrictions regarding language or date of publication.
Selection criteria
Randomised controlled trials where more than 50% of participants had primary tumours of the oral cavity or oropharynx, and which
compared two or more radiotherapy regimens, radiotherapy versus other treatment modality, or the addition of radiotherapy to other
treatment modalities.
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Data collection and analysis
Data extraction and assessment of risk of bias was undertaken independently by two or more authors. Study authors were contacted
for additional information as required. Adverse events data were collected from published trials.
Main results
30 trials involving 6535 participants were included. Seventeen trials compared some form of altered fractionation (hyperfractionation/
accelerated) radiotherapy with conventional radiotherapy; three trials compared different altered fractionation regimens; one trial
compared timingof radiotherapy, five trials evaluatedneutron therapy and four trials evaluated the addition of pre-operative radiotherapy.
Pooling trials of any altered fractionation radiotherapy compared to a conventional schedule showed a statistically significant reduction
in total mortality (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76 to 0.98). In addition, a statistically significant difference in
favour of the altered fractionation was shown for the outcome of locoregional control (HR 0.79, 95% CI 0.70 to 0.89). No statistically
significant difference was shown for disease free survival.
No statistically significant difference was shown for any other comparison.
Authors’ conclusions
Altered fractionation radiotherapy is associated with an improvement in overall survival and locoregional control in patients with oral
cavity and oropharyngeal cancers. More accurate methods of reporting adverse events are needed in order to truly assess the clinical
performance of different radiotherapy regimens.
P L A I N L A N G U A G E S U M M A R Y
Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy
Oral cavity (mouth) cancer is usually detected earlier and treated with surgery and radiotherapy. Oropharyngeal (throat) cancer may
be at an advanced stage when it is found and is treated with radiotherapy. Both surgery and radiotherapy may be associated with
disfigurement and decreased ability to eat, drink and talk. Recent advances show that by altering how the radiotherapy is given to
patients, improvements in overall survival can be achieved. The new methods of giving radiotherapy are called accelerated fractionation
or hyperfractionation. However, they may be associated with an increase in side effects.
2Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Altered fractionation compared with conventional radiotherapy for the treatment of oral cavity and oropharyngeal cancer
Patient or population: people with oral cavity and oropharyngeal cancer
Settings: hospital
Intervention: altered fractionation
Comparison: conventional
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Conventional Altered fractionation
Mortality
(follow-up: 5 years)
Low risk population HR 0.86 (0.76 to 0.98) [3751]
(13)
+OOO
very low2,3,4
Analysis conducted on all
included studies
200 per 10001 175 per 1000
(156 to 196)
Medium risk population
500 per 1000 449 per 1000
(410 to 493)
High risk population
700 per 10001 645 per 1000
(599 to 693)
Mortality
(follow-up: 5 years)
Low risk population HR 0.93 (0.80 to 1.07) [1511]
(5)
+++O
moderate2
Analysis conducted for
studies at low risk of bias
200 per 10001 187 per 1000
(163 to 212)
Medium risk population
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500 per 1000 475 per 1000
(426 to 524)
High risk population
700 per 10001 674 per 1000
(618 to 724)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HR: hazard ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Based on data presented by McGurk 2005
2Studies included patients with other head and neck cancers
3Heterogeneity due to one study
4Assessed as unclear regarding allocation concealment, incomplete outcome data, selective reporting and/or other biases for 8 included
trials
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B A C K G R O U N D
Description of the condition
Oral cancers are a significant disease group globally with more
than 404,000 new cases worldwide in 2002 (Parkin 2005;
Warnakulasuriya 2009). Oral cancers are the sixth most common
cancer worldwide, accounting for an estimated 4% of all cancers.
The incidence and mortality from oral cancers varies geographi-
cally; the highest age standardised rates of oral cancers are reported
in parts of Europe (France, Hungary), Botswana and south central
Asia (Sri Lanka, Pakistan, Bangladesh and India) (Parkin 2005).
There is overwhelming evidence that tobacco use, alcohol con-
sumption and betel quid chewing are the main risk factors in the
aetiology of intraoral cancer (La Vecchia 1997; Macfarlane 1995).
There is also strong evidence that low socio-economic status is
associated with a higher incidence and poorer survival of oral can-
cers (Faggiano 1997). There is a higher incidence of oral cancers
in men (Freedman 2007) that is generally attributed to a greater
exposure to the known risk factors and vast majority of cases occur
in men over 50 (Warnakulasuriya 2009) and among low socio-
economic groups (Conway 2008). However, the ratio of males to
females diagnosed with oral cancers has declined from approxi-
mately 5:1 in the 1960s to less than 2:1 in 2002 (Parkin 2005).
Another recent trend is the increasing incidence of oral cavity and
oropharyngeal cancers in younger adults in the European Union
and the United States (Warnakulasuriya 2009).
The epidemiological data concerning ’oral cancer’ obscure the fact
that ’oral cancer’ includes both oral cavity and oropharyngeal can-
cers which have clinically different aetiology, are generally diag-
nosed at different stages and managed in different ways. Patients
with oral cavity cancers generally present with early stage disease
and the primary treatment is surgery or radiotherapy or both.
However, oropharyngeal cancers are likely to be advanced at the
time of diagnosis and primary treatment is more likely to be ra-
diation therapy or chemoradiation. It is now recognised that oral
infection with human papilloma virus (HPV) is strongly associ-
ated with the development of oropharyngeal cancer where HPV
infection is found in 40% to 60% of patients (D’Souza 2007),
and HPV is thought to be associated with the increased inci-
dence of oropharyngeal cancer (Hammarstedt 2006). The link be-
tween oncogenic HPV and oropharyngeal cancer is strong and has
been documented in numerous studies, fulfilling the epidemiolog-
ical criteria for disease causality, especially in the development of
oropharyngeal cancer in non-smokers (Sturgis 2007). The propor-
tion of patients with oropharyngeal cancer who are HPV positive
has increased dramatically over recent years (Attner 2010; Ryerson
2008) but it is interesting to note that this group of patients have
significantly improved rates of both overall survival and disease
free survival (Fakhry 2006; Fakhry 2008; Licitra 2006).
The most common cancer of the oral cavity is the squamous cell
carcinoma that arises from the lining of the oral cavity; over 95%
of all oral cavity cancers are squamous cell carcinomas. Despite
significant technical advances in the treatment of oral cancer, it
still has a significant mortality with 128,000 deaths recorded, rep-
resenting nearly half of the incident cases (48%) (Parkin 2001).
Survival following a diagnosis of oral cavity or oropharyngeal can-
cer remains poor with 5-year survival around 50% overall, with
only limited improvement in the past 3 decades (Warnakulasuriya
2009).
Description of the intervention
Surgery has long been the mainstay for the treatment of oral can-
cer but radiotherapy can be used alone, in combination (adjuvant)
with surgery, or in combination with chemotherapy (Garg 2004).
Radiotherapy (also referred to as radiation therapy) is a localised
treatment and thereby affects cells only in the treated area. Radio-
therapy is used alone for small tumours or for patients who cannot
have surgery. It may be used before surgery to kill cancer cells and
shrink the tumour. It also may be used after surgery to destroy
cancer cells that may remain in the area.
Radiotherapy works by damaging the deoxyribonucleic acid
(DNA) of rapidly dividing cells so that the usual mechanisms of
DNA repair (which are usually less effective in cancer cells com-
pared to normal cells) cannot work and the cells die. However,
normal cells that proliferate rapidly will inevitably be affected by
therapeutic radiation. Therefore tissues such as hair, salivary glands
and the mucosa are commonly affected (CRUK 2009).
Conventional radiotherapy uses high-energy photons to kill cancer
cells. Two types of radiotherapy are commonly used to treat oral
and oropharyngeal cancers: teletherapy - where the radiation is
produced by a linear accelerator machine (external beam). Patients
undergoing this type of therapy have to go to the hospital or
clinic daily, usually 5 days a week for several weeks. Alternatively
they may receive radiotherapy in the form of brachytherapy (also
referred to as implant radiotherapy). Here the radiation comes
from a radioactive material placed in seeds, needles, or carried via
thin plastic tubes and put directly into the tissue. The patientmust
stay in hospital for the duration of the implant therapy, typically
several days. Some people with oral cancer have both kinds of
radiation therapy.
Radiotherapy for the treatment of head and neck cancer has con-
ventionally been given as single daily doses of 1.8 to 2.0 Gy/frac-
tion, 5 days a week to a total dose of 66 to 70 Gy (over 6½ to
7 weeks). This method of dividing up the total dose, or fraction-
ation, has been modified over the years based on the underlying
biology of the tumours and normal host tissues and has been re-
cently reviewed by Bernier (Bernier 2005; Bernier 2006). There
are twomain types of altered fractionation: hyperfractionation and
accelerated fractionation. Hyperfractionation uses smaller, multi-
ple daily doses over a similar duration as conventional fractiona-
tion to give a higher total dose. Typically twice daily fractions of
1.1 to 1.2 Gy/fraction to a total dose of 74 to 80 Gy are used.
Accelerated fractionation uses similar total doses as conventional
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treatment in a reduced treatment time. Accelerated radiotherapy
schedules have been developed recently to overcome tumour cell
repopulation during the course of therapy (squamous cell can-
cers of the head and neck can double the number of cancerous
cells in 3 days) (Bourhis 2006). Further variations have been at-
tempted: continuous hyperfractionated accelerated radiotherapy
(CHART), intensity modulated radiotherapy (IMRT) and image-
guided radiotherapy (CRUK 2009; Harari 2005).
When used as an adjuvant to surgery, radiotherapy has tradition-
ally been given post-operatively particularly when there has been
incomplete excision or there is extracapsular spread of the tu-
mour out of the cervical lymph nodes. Neoadjuvant radiotherapy
(given before surgery) is less common because of the deleterious
effects on the tissues making surgery more difficult. Studies have
shown improved survival in combination therapywhere radiother-
apy is given post-operatively rather than pre-operatively (Fanucchi
2006).
Tumours can be resistant to radiotherapy for a variety of reasons.
Very rapidly proliferating tumour cells can repopulate in between
treatments (hence the case for hyperfractionation), tumour cells
can be intrinsically resistant to radiation or the tumours may be
hypoxic (oxygen is required to enhance the DNA damage of the
radiotherapy). In view of this, chemotherapy can be added to
enhance the action of radiotherapy.
Why it is important to do this review
The management of advanced oral cavity and oropharyngeal can-
cers is problematic and has traditionally relied on surgery and ra-
diotherapy, both of which are associated with substantial adverse
effects. Although there have been new treatments developed there
has been limited improvement in survival over the past 3 decades
(Warnakulasuriya 2009). Oropharyngeal cancers have relatively
’silent’ symptoms which may not be present during the early stages
of the disease, which is a possible explanation for the fact that
stage of disease at diagnosis has not altered in the past 40 years
despite public education (McGurk 2005). Tumour recurrence and
the development ofmultiple primary tumours are themajor causes
of treatment failure (Day 1992; Partridge 2000; Woolgar 2003).
Surgical treatment may be disfiguring and result in a substantially
reduced quality of life as patients are socially isolated, due to diffi-
culties with altered appearance, speech, eating and drinking. De-
velopments in the way in which radiotherapy is delivered aim to
improve its efficacy and maintain acceptable levels of toxicity.
This review is undertaken as part of a series of reviews looking at
the different treatment modalities of oral cancer (Furness 2010;
Oliver 2007; Pavitt 2007). These reviews have been categorised
into four intervention groups: surgery, chemotherapy, radiother-
apy and immunotherapy. For this radiotherapy review we will aim
to answer the broad question ’Does treatment with radiotherapy,
in addition to chemotherapy and/or surgery, improve the out-
comes for patients with oral cavity and oropharyngeal cancers?’.
O B J E C T I V E S
Primary objective
To determine which radiotherapy regimens for oral cavity and
oropharyngeal cancers result in increased overall survival, disease
free survival, progression free survival and locoregional control.
Secondary objective
To determine the implication of treatment modalities in terms of
morbidity, quality of life, costs, hospital days of treatment, com-
plications and harms.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials comparing radiotherapy to an alter-
native radiotherapy regimen or other treatment modality, or trials
evaluating the addition of radiotherapy to other treatment modal-
ities (including surgery and chemotherapy). Trials with a mini-
mum follow-up of 6 months will be included. It is anticipated
that there will be no studies comparing radiotherapy with placebo
(although if there are such studies they will be included).
Types of participants
Patients with oral cancer as defined by the International Classifica-
tion of Diseases for Oncology (ICD-O) codes as C01-C02, C03,
C04, C05-C06 (oral cavity) and cancer of the oropharynx (ICD-
O: C09, C10) will be included but hypopharynx (ICD-O: C13),
nasopharynx (ICD-O: C11) and larynx (ICD-O: C32) will be
excluded. Cancers of the lip (ICD-O: C00) will also be excluded
(WHO 1992).
Studies of head and neck cancer with cases of oral cancer will
be included (so long as at least 50% of participants who have
oral cavity or oropharyngeal cancer are included, or data for these
cancers alone are available separately).
Cancers will be primary squamous cell carcinomas arising from
the oralmucosa.Histological variants of squamous cell carcinomas
will be included (adenosquamous, verrucous, basaloid, papillary
etc) although they are known to have differing natural history to
the majority of conventional squamous cell carcinomas they have
a common aetiology, their incidence is low and they are generally
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managed in the same way. Carcinoma in situ will be included. Ep-
ithelial malignancies of the salivary glands, odontogenic tumours,
all sarcomas and lymphomas will be excluded as these have a dif-
ferent aetiology and are managed differently.
Types of interventions
Radiotherapy: any mode of administration, dose of fractionation
and total dose, number of fractions per day and per week, and
duration of radiotherapy will be included.
Comparisons were made between different radiotherapy regimens
and radiotherapy versus other treatment modalities including
surgery and chemotherapy. The addition of radiotherapy to other
treatment modalities were also be evaluated.
The intervention under evaluation must be radiotherapy. Trials
where all participants receive the same radiotherapy regimen and
are randomised to other treatments were excluded. Trials evaluat-
ing the role of chemoradiotherapy compared to radiotherapy alone
are covered in the chemotherapy review by Furness 2010.
The treatments received and compared must be the primary treat-
ment for the tumour and patients should not have received any
prior intervention other than diagnostic biopsy.
Types of outcome measures
Primary outcome measures
• Overall survival/total mortality (disease related mortality
will also be studied if possible).
• Locoregional control.
• Disease free survival.
• Progression free survival or time to recurrence.
Secondary outcome measures
• Quality of life.
• Harms associated with treatment.
• Direct and indirect costs to patients and health services.
• Patient satisfaction.
Search methods for identification of studies
Electronic searches
This review is part of a series of Cochrane reviews on the treatment
modalities for treating oral cavity and oropharyngeal cancer. The
reviews have been broadly divided into four themes concerning
surgery, chemotherapy, radiotherapy or immunotherapy/targeted
therapies. A search strategy was developed that would encompass
three of the four broad themes simultaneously (surgery, chemo-
therapy, radiotherapy) and further adapted for use in the following
databases (date of the most recent searches as indicated):
• The Cochrane Oral Health Group’s Trials Register (to 28
July 2010) (Appendix 2)
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2010, Issue 3) (Appendix 3)
• MEDLINE via OVID (1950 to 28 July 2010) (Appendix 1)
• EMBASE via OVID (1980 to 28 July 2010) (Appendix 4).
Current Controlled Trials (www.controlled-trials.com) was
searched for oral cancer or oropharyngeal cancer on 25 January
2010.
Because studies involving oral cancer are often included with those
of the head and neck, a broad search was undertaken to include
all possible studies. The searches attempted to identify all rele-
vant trials irrespective of language. The reference list of related re-
view articles and articles considered to be potentially relevant were
checked for further trials. Authors of identified trials and known
specialists in the field were contacted in an attempt to identify any
additional published or unpublished trials.
Sensitive search strategies were developed for each database using a
combination of free text andMeSH terms; these were based on the
search strategy developed forMEDLINE (Appendix 1) but revised
appropriately for each database. The search strategy combined the
subject search with the Cochrane Highly Sensitive Search Strategy
(CHSSS) for identifying randomised trials in MEDLINE: sensi-
tivity maximising version (2009 revision) as referenced in Chapter
6.4.11.1 and detailed in box 6.4.c of the Cochrane Handbook for
Systematic Reviews of Interventions version 5.0.2 (updated Septem-
ber 2009) (Higgins 2009). The search of EMBASE was linked to
theCochrane OralHealthGroup filter for identifying randomised
controlled trials in this database (Appendix 4).
Handsearching was done as part of the Cochrane Collaboration’s
worldwide handsearching programme, see the Cochrane Master
List of journals being searched formore information.The reference
lists of related reviews and all articles obtained were checked for
further trials. Authors of trial reports and specialists in the field
known to the review authors were written to concerning further
published and unpublished trials.
Data collection and analysis
Selection of studies
The titles and abstracts (when available) of all reports identified
through the electronic searches were scanned independently by
two review authors. For studies appearing to meet the inclusion
criteria, or for which there were insufficient data in the title and
abstract to make a clear decision, the full report was obtained. The
full reports obtained from all the electronic and other methods
of searching were assessed independently by two review authors
to establish whether the studies met the inclusion criteria or not.
Disagreements were resolved by discussion. Where resolution was
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not possible, a third review author was consulted. All studies meet-
ing the inclusion criteria underwent a risk of bias assessment and
data extraction using a specially designed data extraction form.
Studies rejected at this or subsequent stages were recorded in the
Characteristics of excluded studies table, and reasons for exclusion
recorded.
Data extraction and management
Data were extracted by two review authors independently using
specially designeddata extraction forms.The data extraction forms
were piloted on several papers and modified as required before
use. Any disagreements were discussed and a third review author
consulted where necessary. However, group discussion was often
required following data extraction due to the complexity of the
data presented. When necessary authors were contacted for clari-
fication or missing information.
For each trial the following data were recorded:
• Year of publication, country of origin and source of study
funding
• Details of the participants including demographic
characteristics and criteria for inclusion and exclusion,
proportion with oral cavity and oropharyngeal cancer
• Details of the type of intervention, timing and duration
• Details of the outcomes reported, including method of
assessment, and time intervals.
As the majority of trials were for head and neck cancers the pro-
portion of oral/oropharyngeal cancer patients was recorded (Ad-
ditional Table 1). Head and neck cancer trials with only combined
data (i.e. no outcome data available by primary tumour site) where
greater than 50% of participants presented with oral/oropharyn-
geal cancer were included in this review. However, where separate
’pure’ oral/oropharyngeal cancer data were available for a trial,
these ’pure’ data were extracted and analysed and the combined
head and neck data ignored.
Assessment of risk of bias in included studies
For the studies included in this review assessment of risk of bias was
conducted by two review authors using the Cochrane risk of bias
assessment tool. Six domainswere assessed for each included study:
sequence generation, allocation concealment, blinding, complete-
ness of outcome data, risk of selective outcome reporting and risk
of other potential sources of bias.
A description of the domains was tabulated for each included trial,
along with a judgement of low, high or unclear risk of bias. For
example, criteria for risk of bias judgements regarding allocation
concealment are given below as described in the Cochrane Hand-
book for Systematic Reviews of Interventions 5.0.2 (Higgins 2009).
• Low risk of bias - adequate concealment of the allocation
(e.g. sequentially numbered, sealed, opaque envelopes or
centralised or pharmacy-controlled randomisation).
• Unclear risk of bias - unclear about whether the allocation
was adequately concealed (e.g. where the method of concealment
is not described or not described in sufficient detail to allow a
definite judgement).
• High risk of bias - inadequate allocation concealment (e.g.
open random number lists or quasi-randomisation such as
alternate days, date of birth, or case record number).
A summary assessment of the risk of bias for the primary outcome
(across domains) across studies was undertaken (Higgins 2009).
Within a study, a summary assessment of low risk of bias was given
when there was a low risk of bias for all key domains, unclear risk
of bias when there was an unclear risk of bias for one or more key
domains, and high risk of bias when there was a high risk of bias
for one or more key domains.
Measures of treatment effect
The primary outcome is total mortality expressed as a hazard ratio
(it is acknowledged that it is preferable to talk in terms of overall
survival, however, statistically the estimate of effect is the hazard
ratio of death). If hazard ratios were not quoted in studies, we
calculated the log hazard ratio and the standard error (SE) from the
available summary statistics or Kaplan-Meier curves, according to
the methods proposed by Parmar et al (Parmar 1998), or these
data were requested from authors. A meta-analysis of individual
patient data (IPD) for altered fractionation versus conventional
fractionation has previously been published (Bourhis 2006). For
trials included in the Bourhis meta-analysis, the IPD were used
instead of data presented in the published reports of the individual
trials.
For dichotomous outcomes, the estimates of effect of an interven-
tion were expressed as risk ratios together with 95% confidence
intervals. Dichotomous data were only used for primary outcomes
where hazard ratios were unavailable or could not be calculated.
Assessment of heterogeneity
Meta-analyses were conducted only if there were studies of similar
comparisons reporting the same outcome measures. The signifi-
cance of any discrepancies in the estimates of the treatment effects
from the different trials was assessed by means of Cochran’s test
for heterogeneity and the I2 statistic, and any heterogeneity inves-
tigated.
Data synthesis
Risk ratios were combined for dichotomous data, and hazard ratios
for survival data, using a fixed-effectmodel, unless there weremore
than four trials to be combined, when a random-effects model was
used. Hazard ratio data were entered into the meta-analysis using
the inverse variance method.
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Subgroup analysis and investigation of heterogeneity
Due to the different natural history and treatment regimens for
oral cavity and oropharyngeal cancers we planned to analyse these
cancer types separately, if there were sufficient data.
Sensitivity analysis
A sensitivity analysis (to examine the effects of randomisation, allo-
cation concealment, blinded outcome assessment (if appropriate)
and quality of follow-up/completeness of data set) was planned.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Over 5000 research papers were identified through the electronic
searching. Screening of the titles and abstracts resulted in the iden-
tification of 129 potentially relevant trials for inclusion in the re-
view. Full text copies of these articles were retrieved, where avail-
able. Further assessment of the papers resulted in 30 trials (from
68 publications) being included int he review. Forty-one trials
(from 63 publications) were excluded, the reasons for which are
presented in Characteristics of excluded studies.
Of the 30 trials included in the review, 19 were multicentred, with
the number of centres ranging from 2 to 26. Fourteen trials were
undertaken in the US (one linked with centres in Canada and one
linked to the UK), four in centres across Europe, two in Italy, two
in Germany, two in India, one across Australia and NewZealand
and one solely in the UK, France, Japan, Brazil, and Poland.
Participants were recruited over periods ranging from 1 year to
10 years, with the earliest recruitment commencing in 1969 (
Lawrence 1974; Terz 1981).
Fifteen of the included trials reported the cancer stage of recruited
participants. Five of the trials recruited those with stages II-IV,
nine included patients with stages III-IV and one trial recruited
those with stages I-IV. Tumour extent (TNM) was reported in 25
of the included trials, 13 of which included patients with T1 to
T4 tumours. The remaining 12 included T2 to T4 or T3 to T4.
Of the 30 included trials, only two included recruited participants
with oral cavity cancer only and a further four included only those
with oropharyngeal cancer. The authors of two trials provided us
with separate data (see Additional Table 1 for details) and one
trial recruited only those with cancer of either the oral cavity or
oropharynx. In the remaining included trials at least 50% of par-
ticipants had either oral cavity or oropharyngeal cancer.
Trials were grouped into five main categories.
Altered fractionation
• Hyperfractionated versus conventional (Fu 2000; Horiot
1992; Pinto 1991).
• Hyperfractionated/accelerated versus conventional (Bourhis
2006; Dobrowsky 2000; Marcial 1987; Poulsen 2001).
• Hyperfractionated/accelerated/split versus conventional
(Bartelink 2002; Fu 2000; Horiot 1997; Olmi 2003).
• Accelerated versus conventional (Skladowski 2006;
Weissberg 1983).
• Accelerated/boost versus conventional (Ang 2001; Fu 2000;
Ghoshal 2008; Sanguineti 2005).
• Accelerated/split versus conventional (Marcial 1993).
• Hyperfractionated/accelerated split course radiotherapy
versus accelerated boost (Fu 1995).
• Split course versus accelerated (Hukku 1991).
• Variable total dose/duration (Cox 1990).
Note: Conventional radiotherapy was defined as 66-77 Gy in 2 Gy
fractions, for 5 days a week.
Neutron therapy
• Mixed beam versus photon (Griffin 1989).
• Neutron versus photon (Griffin 1984; MacDougall 1990;
Maor 1986; Maor 1995).
Pre-operative radiotherapy
• Pre-operative radiotherapy versus surgery alone (Ketcham
1969; Lawrence 1974; Terz 1981).
• Pre-operative and post-operative radiotherapy versus post-
operative radiotherapy alone (Bergermann 1992).
Timing of radiotherapy regimen
• Morning radiotherapy versus afternoon radiotherapy
(Bjarnason 2009).
Other
• Low dose rate interstitial radiotherapy versus high dose rate
interstitial radiotherapy (Inoue 2001).
Risk of bias in included studies
A summary of the risk of bias assessment is presented in Figure 1.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Eighteen of the included trials were assessed as having adequate
sequence generation. In the remaining 12 trials, the sequence gen-
eration was considered to be unclear. Fourteen trials were assessed
as having adequate allocation concealment, the remaining trials
providing insufficient information on this item.
Blinding
In most trials of radiotherapy, blinding of participants and clini-
cians would be difficult. A decision was made to assess those not
explicitly reporting on blinding of outcome assessors as having no
blinding. It was felt that for objective outcomes (such as total mor-
tality) the lack of blinding was unlikely to result in bias. However,
for more subjective outcomes, lack of blinding was considered to
represent a potential risk of bias. Only one trial reported blind
outcome assessment (Ketcham 1969).
Incomplete outcome data
Twelve of the included trials were assessed as being at an unclear
risk of bias with regard to incomplete outcome data. All other trials
were assessed as low risk with regard to this item, due to no miss-
ing outcome data, balanced missing outcome data across groups,
missing outcome data unlikely to be related to true outcome, or
unlikely to have clinical impact on estimate of effect.
Selective reporting
Majority of the included trials (24/30)were assessed as being free of
selective reporting bias, reporting on expected, clinically important
outcomes. Six trials were assessed as being at unclear risk of bias for
this item due to reasons such as lack of information to determine
if subgroup analyses were preplanned.
Other potential sources of bias
Five trials were assessed as being at high risk of bias with regard
to other potential sources of bias (Bergermann 1992; Fu 1995;
Ketcham1969;Maor 1986;Marcial 1987). Fourteenwere assessed
as being at low risk of bias with regard to other potential sources
of bias and 11 trials assessed as unclear risk of bias.
The overall assessment of risk of bias in the included trials is de-
scribed within the section Effects of interventions.
Effects of interventions
See: Summary of findings for the main comparison
Altered fractionation
Within this section trials have been grouped to ensure they are
similar in terms of dose/fraction (Gy), fractions/week, total dose
(Gy) and duration of radiotherapy. The following definitions have
been used.
• Conventional - single daily doses of 1.8 to 2.0 Gy/fraction,
5 days a week to a total dose of 66 to 70 Gy (typically over 6½ to
7 weeks).
• Hyperfractionated - total dose is divided into small doses,
with more than 1 fraction/day.
• Accelerated - total dose given over a shorter period of time
(< 6 weeks).
Hyperfractionated versus conventional radiotherapy
Three trials were included in this comparison (Fu 2000; Horiot
1992; Pinto 1991), with a total of 966 randomised participants. All
three trials were considered to be at unclear risk of bias with regard
to total mortality. For less objective outcomes, two trials were
considered to be at high risk of bias (Fu 2000; Horiot 1992) and
one trial at unclear risk of bias (Pinto 1991). Two trials included
patients with primary tumours of the oropharynx only (Horiot
1992; Pinto 1991). Fu 2000 included patients with head and neck
tumours, of which 10% were located in the oral cavity and 60%
in the oropharynx. The radiotherapy regimens evaluated in the
three trials are presented in the table below.
Summary of radiotherapy regimens: hyperfractionated versus
conventional radiotherapy
Hyperfractionated Conventional
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/
fraction
Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Fu 2000 1.2 10 81.6 7 2 5 70 7
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(Continued)
Horiot
1992
1.15 10 80.5 7 1.75-2 5 70 7-8
Pinto 1991 1.1 10 70.4 6.4 2 5 66 6.5
For all three trials individual patient data (IPD) were available
from Bourhis 2006 for total mortality and locoregional control.
A statistically significant difference was shown in favour of the
hyperfractionated radiotherapy for both total mortality (hazard
ratio (HR) 0.78, 95% confidence interval (CI) 0.68 to 0.90) and
locoregional control (HR 0.74, 95% CI 0.62 to 0.89) (Analysis
1.1; Analysis 1.2).
Disease free survival data were available for one of the trials (Fu
2000) and showed no statistically significant difference between
hyperfractionated and conventional radiotherapy (Analysis 1.3).
Hyperfractionated/accelerated versus conventional
Four trials compared a hyperfractionated/accelerated radiother-
apy regimen with conventional radiotherapy (Bourhis 2006;
Dobrowsky 2000; Marcial 1987; Poulsen 2001), with a total of
1071 randomised participants. Three trials were considered to be
at low risk of bias with regard to assessment of total mortality
(Bourhis 2006; Dobrowsky 2000; Poulsen 2001) and high risk
of bias for other outcomes. Marcial 1987 was considered to be at
high risk of bias across all outcomes.
All trials recruited patients with tumours of the head and neck.
The percentage of participants with cancer of the oral cavity or
oropharynx ranged from 61% (Marcial 1987) to 91% (Bourhis
2006). The radiotherapy regimens are presented in the table below.
Both arms in the trial by Poulsen 2001 received a reduced total
dose in comparison to the other three trials.
Summary of radiotherapy regimens:
hyperfractionated/accelerated versus conventional
radiotherapy
Hyperfractionated/accelerated Conventional
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/
fraction
Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Bourhis
2006
2 10 62-64 3 2 5 70 7
Do-
browsky
2000
2.5 on day
1 then 1.
65
14 55.3 2.4 2 5 70 7
Marcial
1987
1.2 10 60 5 1.8-2 5 66-73.8 7-8
Poulsen
2001
1.8 14 39.6 2.3 2 5 50 5
IPD for total mortality and locoregional control were available for
all four trials (Bourhis 2006). The pooled HR for total mortality
was not statistically significant (HR 0.87, 95% CI 0.75 to 1.00)
but the pooled estimate for locoregional control just attained sta-
tistical significance (HR 0.84, 95%CI 0.72 to 0.99) (Analysis 1.1;
Analysis 1.2).
Only one of the four trials presented data for disease free sur-
vival (Poulsen 2001). No statistically significant difference be-
tween treatment groups was shown (Analysis 1.3).
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Hyperfractionated/accelerated/split versus conventional
Four trials were included in this comparison (Bartelink 2002;
Fu 2000; Horiot 1997; Olmi 2003), including a total of 1299
randomised participants.
Only one trial was considered to be at low risk of bias with regard
to the assessment of total mortality (Horiot 1997); the remaining
trials were considered to be at unclear risk of bias. With regard to
more subjective outcomes, all trials were considered to be at either
high or unclear risk of bias.
One of these trials recruited participants with cancer of the
oropharynx only (Olmi 2003). The remaining three trials recruited
participants with head and neck cancer with the percentage of
those with cancer of the oral cavity or oropharynx ranging from
71% (Fu 2000) to 80% (Bartelink 2002; Horiot 1997).
The radiotherapy regimens for the five trials are presented in the
table below.
Summary of radiotherapy regimens:
hyperfractionated/accelerated/split versus conventional
radiotherapy
Hyperfractionated/accelerated/split Conventional
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/
fraction
Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Bartelink
2002
1.6 15 72 weeks 1, 4
and 7
2 5 70 7
Fu 2000 1.6 10 67.2 2.5 weeks,
2 weeks
rest then 1.
5 weeks
2 5 70 7
Horiot
1997
1.6 21 (14 af-
ter split)
72 1.1 weeks,
2 weeks
rest then 2.
4 weeks
2 5 70 7
Olmi 2003 1.6 10 64-67.2 2 weeks, 2
weeks
rest then 3
weeks
2 5 66-70 6.5-7
Total mortality and locoregional control data were available for the
calculation of HR in all four the trials; IPD were available for Fu
2000, Horiot 1997 and Olmi 2003 and HR data were calculated
from a Kaplan-Meier graph for Bartelink 2002. No statistically
significant difference was shown between the two radiotherapy
schedules with regard to either total mortality (HR 1.02, 95% CI
0.90 to 1.17) or locoregional control (HR 0.86, 95% CI 0.74 to
1.01) (Analysis 1.1; Analysis 1.2).
Only two of the four trials presented data on disease free survival
(Fu 2000; Olmi 2003). The radiotherapy schedules were similar
in both trials. Fu 2000 recruited 542 participants with head and
neck cancers (10% oral cavity, 60% oropharynx) to the two ra-
diotherapy regimens, and Olmi 2003 recruited 192 participants
with cancer of the oropharynx. The results with regard to disease
free survival are contradictory, with substantial statistical hetero-
geneity (P = 0.02, I2 = 82%) (Analysis 1.3).
Accelerated versus conventional
Two trials compared an accelerated regimen (with no split, boost or
hyperfractionation) with conventional radiotherapy (Skladowski
2006; Weissberg 1983), including a total of 164 randomised par-
ticipants.
Both trials were considered to be at unclear risk of bias for the
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assessment of total mortality and high risk of bias for subjective
outcomes.
Both trials recruited participants with head and neck cancer; 64%
of those recruited by Weissberg 1983 and 50% of those recruited
by Skladowski 2006 had tumours of the oral cavity or oropharynx.
The radiotherapy regimens for the two trials are presented in the
table below, and differ substantially. The accelerated course used
by Skladowski 2006 was of longer duration with a higher total
dose than Weissberg 1983. Also, Skladowski 2006 gave a lower
dose/fraction for 7 fractions/week (rather than 5 fractions/week).
The conventional radiotherapy schedules were similar.
Summary of radiotherapy regimens: accelerated versus
conventional radiotherapy
Accelerated Conventional
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/
fraction
Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Weissberg
1983
4 5 40-48 2-3 2 5 60-70 6-7
Sklad-
owski
2006
2 7 66+/-2
(T2)
70+/-2
(T3-4)
4.7-5.1 2 5 66+/-2 (T2)
70+/-2 (T3-
4)
6.7-7.1
Only one trial reported data for total mortality and locoregional
control (Skladowski 2006), for which IPD were also available (
Bourhis 2006). A statistically significant difference in favour of
the altered fractionation was shown (Analysis 1.1; Analysis 1.2).
Both trials reported on disease free survival, however, given the
substantial clinical and statistical heterogeneity between the trials’
results (P = 0.0004, I2 = 92%) a pooled analysis is not reported
here (Analysis 1.3).
Accelerated/boost versus conventional
Four trials compared an accelerated regimen incorporating a ra-
diotherapy boost with conventional radiotherapy (Ang 2001; Fu
2000; Ghoshal 2008; Sanguineti 2005), with a total of 1203 ran-
domised participants.
One trial was assessed as being at low risk of bias with regard
to total mortality (Ang 2001) and three were assessed as being
at unclear risk of bias with regard to total mortality (Fu 2000;
Ghoshal 2008; Sanguineti 2005). For subjective outcomes, all four
trials were considered to be at high risk of bias.
For two of the trials data were available from the authors for those
participants with cancer of the oral cavity or oropharynx only (Ang
2001; Sanguineti 2005). In the trials by Fu 2000 and Ghoshal
2008 71% and 65% of recruited participants had cancer of the
oral cavity or oropharynx.
The radiotherapy regimens for the four trials are presented in
the table below and are similar across trials. However, it should
be noted that in the trials by Ang 2001 and Sanguineti 2005,
radiotherapy was given post-operatively.
Summary of radiotherapy regimens: accelerated/boost versus
conventional radiotherapy
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Accelerated/boost Conventional
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/
fraction
Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Ang 2001* 1.8
1.8 (boost)
5
10 (boost)
63 5
(boost last
21 days of
radiother-
apy)
1.8 5 63 7
Fu 2000 1.8
1.5 (boost)
5
7 (boost)
70.5 6
(boost last
11 days of
radiother-
apy)
2 5 70 7
Ghoshal
2008
1.8
1.5 (boost)
5
5 (boost)
67.5 5
(boost last
21 days of
radiother-
apy)
2 5 66 6.5
Sanguineti
2005*
2
1.4
(first week
boost)
1.6
(fifth week
boost)
5
5 (boost)
64 5
(boost
during first
and fifth
week of ra-
diother-
apy)
2 5 50-60 5-6
* post-operative radiotherapy
Three of the trials provided data for the calculation of HR for
total mortality; IPD were available for one trial (Fu 2000, data
presented in Bourhis 2006) and data were provided by the authors
for two trials (Ang 2001; Sanguineti 2005). No statistically sig-
nificant difference in total mortality between treatment schedules
was shown (HR 0.95, 95% CI 0.80 to 1.13) (Analysis 1.1).
IPD on locoregional control was available for one trial (Fu 2000,
data from Bourhis 2006 ). A statistically significant difference in
favour of the accelerated schedule with boost was shown in this
single study (Analysis 1.2).
All four trials provided data on disease free survival, and the pooled
estimate showed a statistically significant difference on favour of
the accelerated/boost schedule. However, it should be noted that
there is statistical heterogeneity (P = 0.05, I2 = 63%) (Analysis
1.3).
Accelerated/split versus conventional
One trial, recruiting 147 participants, compared split course, ac-
celerated radiotherapy with conventional radiotherapy (Marcial
1993). The trial was assessed as being at unclear risk of bias for the
outcome of total mortality and high risk of bias for more subjec-
tive outcomes. The trial recruited participants with cancer of the
oropharynx only.
Summary of radiotherapy regimens: accelerated/split versus
conventional radiotherapy
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Accelerated/split Conventional
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/
fraction
Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Marcial
1993
3 5 60 2 weeks, 3
weeks
rest then 2
weeks
2-2.2 5 60-66 6
Dichotomous data were available for the calculation of 5 year
risk ratios for total mortality (Additional Table 2). No statistically
significant difference was shownbetween schedules for any of these
outcomes.
Summary: any altered fractionation radiotherapy versus
conventional radiotherapy
When the 13 trials providing data on any altered fractionation
radiotherapy regimen compared to a conventional schedule were
pooled using a random-effects model, a statistically significant
reduction in total mortality was shown (HR 0.86, 95% CI 0.76
to 0.98) (Figure 2). It should be noted that there was statistically
significant heterogeneity between the trials for total mortality (P
= 0.002, I2 = 59%).
Figure 2. Forest plot of comparison: Summary analyses for altered fractionation versus conventional
radiotherapy, outcome: Total mortality.
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Pooling of 11 trials providing data on locoregional control and
comparing any altered schedule with conventional also showed a
statistically significant difference in favour of the altered fraction-
ation (HR 0.79, 95% CI 0.70 to 0.89) (Figure 3). No statistically
significant difference was shown between altered fractionation and
conventional radiotherapy when the eight trials providing data on
disease free survival were combined (HR 0.85, 95% CI 0.70 to
1.03) (Figure 4).
Figure 3. Forest plot of comparison: Summary analyses for altered fractionation versus conventional
radiotherapy, outcome: Locoregional control.
Figure 4. Forest plot of comparison: Summary analyses for altered fractionation versus conventional
radiotherapy, outcome: Disease free survival.
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A sensitivity analysis was undertaken to determine the effect of
excluding trials assessed as being at high or unclear risk of bias
(Additional Table 3). When the five trials assessed as being at low
risk of bias were pooled using a random-effects model, no statis-
tically significant difference in total mortality was shown between
altered fractionation radiotherapy regimens compared to conven-
tional schedules (HR 0.93, 95% CI 0.80 to 1.07). The findings
of the sensitivity analyses for locoregional control and disease free
survival were HR 0.79, 95% CI 0.68 to 0.91 (random-effects
model) and HR 0.95, 95% CI 0.0.74 to 1.22 (fixed-effect model)
respectively.
Summary of altered fractionation regimens versus
conventional radiotherapy with data from more than one trial
Total mortality
Hyperfractionated versus conventional radiotherapy HR 0.78 (95% CI 0.68 to 0.90)
(3 trials)
Hyperfractionated/accelerated versus conventional radiotherapy HR 0.87 (95% CI 0.75 to 1.00)
(4 trials)
Hyperfractionated/accelerated/split versus conventional radio-
therapy
HR 1.02, (95% CI 0.90 to 1.17)
(4 trials)
Accelerated/boost versus conventional radiotherapy HR 0.95 (95% CI 0.80 to 1.13)
(3 trials)
Any altered fractionation versus conventional radiotherapy
(all trials)
HR 0.86 (95% CI 0.76 to 0.98)
(13 trials)
Any altered fractionation versus conventional radiotherapy
(low risk of bias trials)
HR 0.93 (95% CI 0.80 to 1.07)
(5 trials)
Hyperfractionated/accelerated split course radiotherapy
versus accelerated radiotherapy with concomitant boost
One small trial (including 75 randomised participants), designed
as a feasibility study, compared an accelerated split course with an
accelerated schedule with boost (Fu 1995). The trial was assessed
as being at high risk of bias for all outcomes. The trial participants
had head and neck cancer; 61% had cancer of the oral cavity or
oropharynx. The authors report no significant difference between
the schedules in terms of total mortality, locoregional control or
disease free survival, however, data are not presented in a way that
allow for the calculation of HR.
Summary of radiotherapy regimens:
hyperfractionated/accelerated split course versus
accelerated boost
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Hyperfractionated/accelerated split course Accelerated boost
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/fraction Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Fu 1995 1.6 10 67.2 2.5 weeks,
2 weeks
rest then 1.
5 weeks
1.8
1.5 (boost)
5
7 (boost)
70.5 6
(boost last 11
days of radio-
therapy)
Split course versus accelerated
A single trial of head and neck cancer patients (110 randomised
participants; 72% oral cavity or oropharynx) compared a split
course with an accelerated course of radiotherapy (Hukku 1991).
The trial was assessed to be at unclear risk of bias for total mortal-
ity and high risk of bias for locoregional control and disease free
survival. Dichotomous data were available for the calculation of 2-
year risk ratios for total mortality, locoregional control and disease
free survival (Additional Table 2). No statistically significant dif-
ference was shown between schedules for any of these outcomes.
Summary of radiotherapy regimens: split course versus
accelerated
Split course Accelerated
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/
fraction
Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Hukku
1991
2.3 (2.5 af-
ter split)
5 59.5 3 weeks, 2
weeks
rest then 2
weeks
4 5 44 2.1
Variable total dose/duration
One trial compared three different total doses, delivered over vary-
ing times (Cox 1990). A total dose of 72 Gy was considered to
be the conventional dose. Total doses of 76.8 Gy (over 6.4 weeks)
and 67.2 Gy (over 5.6 weeks) were compared with the conven-
tional dose. The trial was considered to be at unclear risk of bias
for total mortality and high risk of bias for subjective outcomes.
Data were available for the calculation of HR for total mortality
and locoregional control (Additional Table 2). No statistically sig-
nificant difference was shown between either of the altered doses
and the conventional dose with regard to total mortality or locore-
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gional control.
Summary of radiotherapy regimens: altered dose versus
conventional dose
Altered dose Conventional dose
Dose/frac-
tion (Gy)
Fractions/
week
Total dose
(Gy)
Total dura-
tion
(weeks)
Dose/
fraction
Fractions/
week
Total dose
(Gy)
Total dura-
tion (weeks)
Cox 1990 1.2 10 76.8 6.4 1.2 10 72 6
Cox 1990 1.2 10 67.2 5.6
Neutron therapy
Mixed beam versus photon
One trial (327 randomised participants) comparedmixedbeam ra-
diotherapywith conventional photon radiotherapy (Griffin 1989).
The trial was assessed as being at unclear risk of bias with regard to
total mortality and high risk of bias for the assessment of locore-
gional control. A total of 79% of those recruited had cancer of the
oral cavity or oropharynx. No statistically significant difference
was shown between the two schedules for either total mortality
(Analysis 3.1) or locoregional control (Additional Table 2).
Neutron versus photon
Four trials compared neutron radiotherapy with conventional
photon radiotherapy, including a total of 531 participants (Griffin
1984; MacDougall 1990; Maor 1986; Maor 1995). All trials were
considered to be at unclear or high risk of bias for the outcome of
total mortality, and high risk of bias for subjective outcomes.
All four trials included participants with head and neck cancer, the
percentage of those with cancer of the oral cavity or oropharynx
varied from 58% (Griffin 1984) to 77% (Maor 1986).
Three of the four trials provided data that allowed for the calcula-
tion of a HR for total mortality (Griffin 1984; Maor 1986; Maor
1995). No statistically significant difference was shown between
neutron or photon radiotherapy (HR 1.10, 95% CI 0.90 to 1.34)
(Analysis 3.1). MacDougall 1990 provided dichotomous data al-
lowing calculation of 5-year risk ratios for total mortality. Again,
no statistically significant difference was shown between the two
groups (Additional Table 2).
Only one trial provided useable data for the outcome of locore-
gional control and disease free survival (MacDougall 1990). 5-year
risk ratios were calculated; no statistically significant differences
were shown for either outcome (Additional Table 2).
Pre-operative radiotherapy
Pre-operative radiotherapy versus surgery alone
Three trials were included in this comparison, including over 470
randomised participants (Ketcham 1969; Lawrence 1974; Terz
1981). All three trials were considered to be at unclear or high
risk of bias for all outcomes. All included participants with head
and neck cancer, the percentage of those with cancer of the oral
cavity or oropharynx varied from 56% (Ketcham 1969) to 77%
(Lawrence 1974).
Only one trial provided data on total mortality in a useable for-
mat (Terz 1981). No statistically significant difference was shown
between the two groups (Additional Table 2). Ketcham 1969 pro-
vides dichotomous data on locoregional control which showed
no statistically significant difference between groups, however, the
timing of the assessment of this outcome is unclear (Additional
Table 2).
Pre-operative and post-operative radiotherapy versus post-
operative radiotherapy alone
One trial was included in this comparison (Bergermann 1992).
The trial, including patients with cancer of the oral cavity alone,
was judged to be at high risk of bias across all outcomes. Data
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were available for the calculation of HRs for total mortality, lo-
coregional control and disease free survival. No statistically signif-
icant difference was seen for any outcome (Additional Table 2).
Timing of radiotherapy
Morning radiotherapy versus afternoon radiotherapy
One trial recruited 216 participants to either morning or after-
noon radiotherapy (Bjarnason 2009). Four different schedules
were used, either 50Gy in 25 fractions, or 60Gy in 25-30 fractions
or 66 Gy in 33 fractions, or 70 Gy in 25 fractions and randomisa-
tion was stratified on planned total dose. The trial was assessed as
being at unclear risk of bias for objective outcomes and high risk
of bias for all other outcomes. The primary aim of the trial was to
assess associated toxicity with the different radiotherapy regimens.
No statistically significant differences were shown in terms of over-
all survival or locoregional control (Additional Table 2). Morning
radiotherapy was associated with significantly less weight loss after
5 months but no statistically significant difference in quality of
life scores (data not reported).
Other
Low dose rate interstitial radiotherapy versus high dose rate
interstitial radiotherapy
One trial randomised 59 patients with early mobile tongue cancer
(Inoue 2001) to receive either low or high dose rate interstitial
radiotherapy. The trial was assessed as being at unclear risk of bias
for total mortality and high risk of bias for all subjective outcomes.
No statistically significant difference was shown for locoregional
control between treatment groups (Additional Table 2).
D I S C U S S I O N
Summary of main results
The main comparison within this review was altered fractionation
radiotherapy and conventional radiotherapy. Pooling of all studies
of altered fractionation versus conventional radiotherapy showed
a statistically significant difference in favour of the altered frac-
tionation for the outcomes of total mortality (hazard ratio (HR)
0.86, 95% confidence interval (CI) 0.76 to 0.98 (random-effects
model)) and locoregional control (HR 0.79, 95% CI 0.70 to 0.89
(random-effects model)). This statistically significant difference
was not shown for disease free survival (the outcome with least
available data), although the direction of effect was towards altered
fractionation.
Comparing the current review’s findings with the earlier individ-
ual patient data (IPD) meta-analysis of hyperfractionated or ac-
celerated radiotherapy in head and neck cancer (Bourhis 2006)
shows similar results, despite slight discrepancies in trials included
and methods used. Bourhis 2006 showed a statistically significant
benefit in terms of total mortality (HR 0.92, 95% CI 0.86 to
0.97 (fixed-effect model)) in favour of altered fractionation ra-
diotherapy compared to conventional radiotherapy. Again, for lo-
coregional control a statistically significant difference in favour of
altered fractionation radiotherapy was shown (HR 0.82, 95% CI
0.77 to 0.88 (fixed-effect model)).
The meta-analysis by Bourhis 2006 reports a significantly higher
survival benefit with hyperfractionated radiotherapy than with ac-
celerated radiotherapy. Trials were classified differently in the cur-
rent review and the meta-analysis by Bourhis 2006, not allowing
for a direct comparison. However, of trials included within the
current review, those classed as purely ’hyperfractionated’ were the
only pooled group to show a statistically significant difference in
favour of the altered fractionation for the outcome of total mor-
tality (HR 0.78, 95% CI 0.68 to 0.90).
Comparisons between mixed beam versus conventional photon
radiotherapy, and neutron versus photon radiotherapy showed no
statistically significant difference between treatment groups for
total mortality, locoregional control or disease free survival. This
supports the findings reported by Duncan 1994 and Koh 1994
in evaluations of neutron therapy trials in a variety of cancers,
including head and neck cancers. Neither show mixed beam or
neutron therapy to be advantageous to photon radiotherapy and
both raise concern over late morbidity associated with neutron
therapy. Current evidence does not justify the use of mixed beam
or neutron therapy for the treatment of head and neck cancers.
The addition of pre-operative radiotherapy was evaluated in four
trials; three looked at pre-operative versus surgery alone (Ketcham
1969; Lawrence 1974; Terz 1981), one evaluated pre-opera-
tive plus post-operative versus post-operative alone (Bergermann
1992). All trials were considered to be at unclear or high risk of bias
and showed no statistically significant difference for any reported
outcome. There is insufficient evidence to support or refute the
addition of pre-operative radiotherapy for the treatment of cancer
of the oral cavity or oropharynx.
Similarly, there is insufficient evidence to support or refute the
use of high dose rate interstitial radiotherapy over low dose rate
interstitial radiotherapy (Inoue 2001).
Overall completeness and applicability of
evidence
A limitation of the review is that it aims to evaluate the role of
radiotherapy for the treatment of cancers of the oral cavity and
oropharynx. The prevalence of trials of treatments of combined
head and neck malignancies suggests that those undertaking the
primary studies seldom confine trials to patients with a primary
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lesion in either oral cavity or oropharynx, probably for pragmatic
reasons. Of the 30 included trials only two included recruited par-
ticipants with oral cavity cancer only and a further four included
only those with oropharyngeal cancer. The authors of two trials
provided us with separate data (see Additional Table 1 for details)
and one trial recruited only those with cancer of either the oral
cavity or oropharynx. In the remaining included trials at least 50%
of participants had either oral cavity or oropharyngeal cancer. As
for previous reviews assessing the effectiveness of surgery and che-
motherapy for the treatment of patients with cancers of the oral
cavity/oropharynx, we have included these trials because we be-
lieve that they still contribute important information in the ab-
sence of separate data in the research literature. We acknowledge
that data on oral cavity cancers or oropharynx cancers alone may
provide better evidence upon which to inform clinical practice,
and we encourage that in future researchers publish the data for
the different primary tumour sites separately. A subgroup analysis
was undertaken in the IPD meta-analysis by Bourhis 2006. They
report that the effect of altered fractionation on tumour control,
when compared to conventional radiotherapy, did not differ sig-
nificantly according to tumour site (oral cavity, oropharynx, lar-
ynx, hypopharynx).
This review does not present a comprehensive systematic review
of adverse event data, but does report toxicity data presented in
the included trials. The reporting of adverse events within the in-
cluded trials varied greatly. It has previously been acknowledged
that reliable collection and reporting on adverse events remains
challenging for clinical trials in oncology, with no uniformmethod
being used for summarising the key elements of such data (Trotti
2007). Adverse effects from radiotherapy are usually considered in
two groups: acute effects, which occur within 90 days of the start
of treatment and late effects which occur more than 90 days after
the start of treatment. In general acute adverse effects of radio-
therapy include mucositis and skin reactions. Late effects include
fibrosis, necrosis, myelitis, xerostomia or dysphagia. However, this
classification of acute and late adverse effects was developed to re-
flect observations from conventional fractionation. The develop-
ment of altered fractionation and combined modality treatment
has lead to the reporting of extended acute effects, lasting beyond
90 days (Trotti 2000).
The severity of acute adverse effects is increased with increased
daily dose, both with schedules that use increased dose per fraction
and those that include more than one radiotherapy fraction per
day. Lengthening the interfraction interval to at least 6 hours ap-
pears to mitigate some of this increased acute toxicity. A treatment
’rest’, as in split course regimens, does not appear to reduce acute
toxicity.
Late adverse effects are alsomore severe in the accelerated regimens
which use dose/fraction greater than 1.1 Gy and short (< 5 hours)
interfraction interval. This is supported by Ang 2001 who reports
on a large body of radiobiologic data “showing that fraction size
rather than radiotherapy duration is the major determinant of
radiotherapy-induced injury to normal tissues manifesting as late
complications.”
It has been reported that the major limitation of altered fraction-
ation radiotherapy (and combined radio-chemotherapy) for head
and neck cancer is increased acute reaction primarily acute mu-
cositis (Fu 2000). The role of molecular targeted therapies and
improved radiotherapy techniques including intensity modulated
radiotherapy (IMRT) for maintaining acceptable toxicities need
further evaluation. There are currently no trials of IMRT in this
systematic review, however, the PARSPORT trial is underway and
likely to complete follow-up in 2013 (Nutting 2009a).
The management of head and neck cancer often requires a com-
bination of chemotherapy, radiotherapy or surgery, although cur-
rent standard treatment is predominantly chemoradiotherapywith
standard fractionation. This review focuses purely on trials to
which the treatment under evaluation is some form of radiother-
apy. While altered fractionation radiotherapy has been shown to
improve overall survival when compared to conventional radio-
therapy, it has not been directly compared to chemoradiother-
apy. Also, there are no completed trials of altered fractionation
plus chemotherapy versus chemoradiotherapy with standard frac-
tionation. It is perhaps due to the cost and resource considera-
tions of altered fractionation (especially hyperfractionation) that
chemoradiotherapy remains the standard. For patients who have
relative contraindications to chemotherapy (or specifically plat-
inums), there is evidence to recommend the use of altered fraction-
ation radiotherapy alone (especially hyperfractionation). To get a
more complete overview of the role of each treatment modality,
this review needs to be considered alongside the findings of pre-
vious reviews of surgery and chemotherapy for the treatment of
cancers of the oral cavity and oropharynx (Furness 2010; Oliver
2007).
Potential biases in the review process
A comparison between meta-analyses of individual patient data
and data obtained from published literature has previously been
explored (Duchateau 2001). The study focused on meta-analyses
of randomised controlled trials of chemotherapy in head and neck
cancer. The outcome of interest was survival. For themeta-analysis
of individual patient data, the estimate of effect was the hazard
ratio and for the literature-based meta-analysis the odds ratio for
death at particular time point was used. The two meta-analyses
differed substantially in terms of number of comparisons, patients
and events examined. However, even though the data sets vary,
the treatment effect estimates and their 95% confidence intervals
show little variation. The authors report that the main source of
difference between the results of the meta-analyses is due to the
fact that one is based on the hazard ratio and the other on the odds
ratio.
In the current review, the hazard ratio was used as preferred esti-
mate of effect. For 21 of the trials included in the review data for
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the calculation of a hazard ratio were available for the outcome of
total mortality, 15 for locoregional control and 8 for disease free
survival. It is acknowledged that where data are determined from
Kaplan-Meier graphs there is scope for bias. Few trials present
hazard ratios themselves, or data that allow for the calculation of
hazard ratios without having to determine the number of events
from a graph. When available, individual patient data were used
over data presented in the published trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Altered fractionation radiotherapy is associated with an improve-
ment in overall survival and locoregional control in patients with
oral cavity and oropharyngeal cancers. The benefit may be greater
with hyperfractionated regimens rather than accelerated regimens.
More accurate methods of reporting adverse events are needed in
order to truly assess the clinical performance of different radio-
therapy regimens.
Implications for research
The role of molecular targeted therapies and improved radiother-
apy techniques including intensity modulated radiotherapy for
maintaining acceptable toxicities needs further evaluation. In ad-
dition, further research on the relative efficacy and toxicity of al-
tered fractionation radiotherapy (+/- chemotherapy or biologics)
versus conventional chemoradiotherapy is needed, as conventional
chemoradiotherapy is still considered the current standard.
Trialists are encouraged to follow the Consolidated Standards of
Reporting Trials (CONSORT) guidelines when reporting on their
trials. Ideally trials should report hazard ratios with 95% confi-
dence intervals for survival data, or present data that allow for
the calculation of this estimate of effect. In addition, reporting of
outcomes by tumour site and stage would allow for greater under-
standing of patient selection for different treatment modalities.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ang 2001
Methods Location of trial: US.
Number of centres: 3.
Funding: National Cancer Institute (grants CA-06294 and CA-16672), Gilbert H. Fletcher
Chair, and Texas Tobacco Settlement Funds
Trial ID: not stated.
Participants Inclusion criteria: histologically proven squamous cell carcinomaswith advanced cancer (Stage
II-IV) of the oral cavity, oropharynx, larynx or hypopharynx, deemed likely to require treat-
ment with a combination of surgery and post-operative radiotherapy, and having a Zubrod
performance status of 0-2 were eligible for this trial. Median age 57 years
Exclusion criteria: not explicit.
Recruitment period: August 1991 and August 1997.
OC: 80/213 (38%).
OP: 66/213 (31%).
OC+OP: 146/213 (69%) (see notes).
Number randomised: 151.
Number analysed: 151.
Interventions Accelerated radiotherapy with boost versus conventional radiotherapy
Accelerated/boost (n = 76): 1.8 Gy/fraction, 5 fractions per week for 3 weeks, followed by 10
fractions per week for 2 weeks (total 63 Gy)
Conventional (n = 75): 1.8 Gy/fraction, 5 fractions per week for 7 weeks (total 63 Gy)
Median interval between surgery and post-operative radiotherapy was 31 days for those re-
ceiving accelerated radiotherapy and 29 days for those receiving conventional radiotherapy
Outcomes Primary: locoregional control.
Secondary: overall survival, toxicity.
Duration of follow-up: unclear for randomised participants alone
Notes 258 participants underwent surgery and were classified as being low, intermediate or high
risk according to pathologic risk features. Those classed as high risk were randomised to the
2 intervention groups (n = 151)
HR calculated for OC/OP participants only, using data provided by authors
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Randomized trial.“
Not explicitly reported but undertaken by
third party (data provided by author)
Allocation concealment? Yes Third party allocation (data provided by au-
thor).
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Ang 2001 (Continued)
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes All randomised participants included in anal-
ysis.
Free of selective reporting? Yes Important outcomes of locoregional control,
overall survival and toxicity reported
Free of other bias? Yes Groups appear comparable. No other bias ap-
parent.
Bartelink 2002
Methods Location of trial: Europe.
Number of centres: 11.
Funding: not stated.
Trial ID: not stated (EORTC trial).
Participants Inclusion criteria: locally advanced, inoperable head & neck cancer with primaries in oral
cavity, oropharynx, larynx and hypopharynx. T2-T4 included
Exclusion criteria: not explicit.
Recruitment period: not stated.
OC: 16/49 (33%).
OP: 23/49 (47%).
OC+OP: 39/49 (80%).
Number randomised: 53.
Number analysed: 49.
Interventions Hyperfractionated/accelerated/split course radiotherapy plus chemotherapy versus con-
ventional radiotherapy plus chemotherapy
Hyperfractionated/accelerated/split (n = 25): 1.6 Gy per fraction, 3 fractions per day on weeks
1, 4 & 7 (total dose 72 Gy) with 10 mg/m2 cisplatin IV administered daily between fractions
1 & 2. Interfraction interval varied between 3 & 4 hours
Conventional (n = 24): 2 Gy per fraction, 5 fractions per week for a total dose of 70 Gy over
7 weeks together with 6 mg/m2 cisplatin IV 30-60 minutes prior to RT daily.
Outcomes Primary: toxicity.
Secondary: overall survival, locoregional control.
Duration of follow-up: minimum 24 months.
Notes HR data taken from Kaplan-Meier graphs (numbers at risk presented)
Risk of bias
Item Authors’ judgement Description
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Bartelink 2002 (Continued)
Adequate sequence generation? Unclear ”Patients were randomised between“ -
method of sequence generation not described
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear 3/28 (11%) patients in Gr A and 1/25 (4%)
inGr B did not receive allocated treatment. In
this small trial this may have resulted in dif-
ferences between groups with regard to prog-
nostic factors and introduced bias
Free of selective reporting? Yes Primary outcomes are acute and late side ef-
fects, but also planned and reported treatment
compliance, locoregional control and overall
survival
Free of other bias? Unclear There appear to be differences between treat-
ment groups at baseline eg T stage, location
of primary tumour and degree of tumour dif-
ferentiation. No other bias apparent
Bergermann 1992
Methods Location of trial: Germany.
Number of centres: 2.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: histologically confirmed squamous cell carcinoma, primary tumour, T2,
N0-N2, M0, with no prior treatment. Tumour of the floor of the mouth, tongue edge and
pars alveolaris (lower jaw) were included
Exclusion criteria: not explicitly stated in translation.
Recruitment period: March 1982 to February 1987.
OC: 100%.
Number randomised: 100.
Number analysed: 85.
Interventions Pre-operative radiotherapy plus post-operative radiotherapy versus post-operative ra-
diotherapy alone
Pre-operative (n = 44): 6 Gy on days 1-3 followed by surgery on day 4. From day 21 saturation
radiotherapy of 6 Gy/day (total 60 Gy)
No pre-operative (n = 41): surgery followed by saturation radiotherapy from day 21 of 6 Gy/
day (total 60 Gy)
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Bergermann 1992 (Continued)
Outcomes Primary outcome unclear.
Overall survival, local recurrent disease, regionalmetastases, distantmetastases, second tumour
Duration of follow-up: 9 years.
Notes Data from translation.
Data taken from Kaplan-Meier graphs (no numbers at risk).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Randomly allocated to treatment groups“.
No further information on method of se-
quence generation
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear 15/100 randomised patients excluded from
analysis (6 receiving radiotherapy; 9 not re-
ceiving radiotherapy). Reasons unclear
Free of selective reporting? Yes Trial reports outcomes of overall survival, lo-
cal relapse, regional metastases, distant metas-
tases, secondary tumours. No reporting of
toxicity
Free of other bias? No Substantial differences between groups in lo-
cation of primary tumour
Bjarnason 2009
Methods Location of trial: Canada.
Number of centres: 12.
Funding: National Cancer Institute of Canada.
Trial ID: not stated.
Participants Inclusion criteria: histologically proven squamous cell carcinomas of oral cavity, pharynx,
larynx were eligible to receive radiotherapy without chemotherapy, 2 or more visible areas of
oral mucosa in target area, ECOG performance status 0-1, adequate haematological function.
T1-T4 included
Exclusion criteria: shift workers, patients with abnormal sleep habits, previous radiotherapy
or chemotherapy within 6 months, planned use of radioprotective agents, connective tissue
disease or AIDS
Recruitment period: August 1999 to November 2002.
OC: 40/216 (19%).
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Bjarnason 2009 (Continued)
OP: 76/216 (35%).
OC+OP: 116/216 (54%).
Number randomised: 216.
Number analysed: 216 (for overall survival); 205 (for toxicity)
Interventions Morning radiotherapy versus afternoon radiotherapy
Morning (n = 108 ): radiotherapy between 8 &10 am.
Afternoon (n = 108 ): radiotherapy between 4 & 6 pm.
4 different schedules were used, either 50 Gy in 25 fractions, or 60 Gy in 25-30 fractions or
66 Gy in 33 fractions of 70 Gy in 25 fractions. Randomisation was stratified on planned total
dose
Outcomes Primary: oral mucositis incidence of grade 3 or higher.
Secondary: interval to development of grade 2 mucositis, duration of various grades of mu-
cositis, treatment days lost due to toxicity, other acute/late toxicities, quality of life, weight
loss during/after treatment, overall survival, locoregional control
Duration of follow-up: maximum 5 years, 7 months.
Notes Sample size calculation: hypothesised that incidence of grade 3 or greater mucositis with
afternoon RT would be 35% and 17.5% for morning RT and it was estimated that 216
patients would be required to detect this difference with 80% power at a 2-sided 0.05 level,
after taking into account a potential 5% withdrawal rate
HR presented in text.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A minimisation procedure was used to ran-
domise patients. Patients were stratified by
treatment centre, pretreatment smoking sta-
tus and planned total radiation dose
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes Gr A 4/108 (4%) patients and Gr B 3/108
(3%) were found to be ineligible. In addition,
Gr B 3/108 did not receive RT & 1/108 had
no mucositis assessments recorded (4%). All
randomised patients were included in survival
outcome
Free of selective reporting? Yes Primary endpoint of study is toxicity, overall
survival is a secondary outcome
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Bjarnason 2009 (Continued)
Free of other bias? Yes Groups appear comparable at baseline. Possi-
ble co-interventions clearly proscribed
Bourhis 2006
Methods Location of trial: France.
Number of centres: 11.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: patients with no previous history of cancer, or previous chemotherapy
or radiotherapy, performance status 0-2, squamous cell cancer of oral cavity, oropharynx,
hypopharynx and larynx, T3-T4, N0-N3 not eligible for surgery
Exclusion criteria: not explicitly stated.
Recruitment period: November 1994 to September 1998.
OC: 36/266 (14%).
OP: 205/266 (77%).
OC+OP: 241/266 (91%).
Number randomised: 268.
Number analysed: 266.
Interventions Hyperfractionated/accelerated radiotherapy versus conventional radiotherapy
Hyperfractionated/accelerated (n = 137): 62-64 Gy in 31-32 fractions over 22-23 days, 2 Gy/
fraction, 2 fraction/day, 20 Gy/week over 3 weeks. Interfraction interval 8 hours
Conventional (n = 129): 70 Gy in 35 fractions, 2 Gy per fraction, over 7 weeks
Outcomes Primary: locoregional control.
Secondary: overall survival, disease free survival, toxicity
Duration of follow-up: median > 6 years.
Notes Sample size calculation ”estimated that a minimum of 100 patients per group would be
necessary to demonstrate an increase in the locoregional tumour control rate, from 30% in
the conventional group to 55% in the very accelerated group, with an α = 5% and β = 5%
(two tailed test).“
Data from Kaplan-Meier figures.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Centrally randomised at Institute Gustave
Roussy Villejeuf, France from a computer
generated list.... randomisation stratified by
centre.“
Allocation concealment? Yes Treatment allocation made by telephone call
to randomisation centre
39Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bourhis 2006 (Continued)
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes 1 patient had missing data, 1 refused treat-
ment, and remainders of those randomised
included in outcome evaluation
Free of selective reporting? Yes Important outcomes planned and reported -
locoregional control, toxicity and overall sur-
vival
Free of other bias? Yes Distribution of important patient and tu-
mour characteristics well balanced between
treatment arms. No other apparent bias
Cox 1990
Methods Location of trial: US.
Number of centres: multicentre (number unclear).
Funding: National Cancer Institute, National Institute for Health (grants 21661, 32115,
12258, 13457, 20235, 21439, 29565, 12262)
Trial ID: RTOG 83-13.
Participants Inclusion criteria: squamous cell carcinoma of the upper aerodigestive tract, Stages III & IV
considered inoperable, with no prior resection or radiotherapy. Adequate bone marrow and
renal function. T1-T4 included
Exclusion criteria: history of previous malignant tumour. Prior chemotherapy within 6 weeks
of randomisation
Recruitment period: April 1983 to February 1986 (Scheme A).
OC: 47/237 (20%).
OP: 104/237 (44%).
OC+OP: 151/237 (64%).
Number randomised: 260.
Number analysed: 237.
Interventions Different doses of hyperfractionated radiotherapy
Gr A (n = 63): 67.2 Gy.
Gr B (n = 58): 72.0 Gy.
Gr C (n = 116): 76.8 Gy.
All fractions were 1.2 Gy given twice daily 5 days per week. Interval between fractions was
permitted to be 4-8 hours. Radiotherapy was administered with photons of 1.25 MV or
greater with minimum source axis distance of 80 cm
Outcomes Primary: locoregional control.
Secondary: overall survival, toxicity, late effects.
Duration of follow-up: minimum 2 years.
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Cox 1990 (Continued)
Notes Trial also randomised patients to 81.6 Gy or 72.0 Gy between February 1986 to November
1987 (Scheme B). However, the trial focuses on data from Scheme A
HR data taken from Kaplan-Meier graphs (no numbers at risk).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Randomized to 1 of 3 total doses“.No details
of method of sequence generation given
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear 9% of patients randomised are excluded from
analysis, but reasons and group allocation not
described
Free of selective reporting? Unclear Multiple publications addressing different
outcomes and exposures
Free of other bias? Unclear Possible contamination due to some patients
having had prior chemotherapy
Dobrowsky 2000
Methods Location of trial: Europe.
Number of centres: 21.
Funding: Medizinischwissenschaftlicher Fonds des Burgermeisters der Bundeshauptstadt
Wien
Trial ID: not stated.
Participants Inclusion criteria: squamous cell cancers originating in head and neck. Most were advanced
tumours with lymph node involvement and were considered inoperable by the referring
specialist. T1-T4 included
Exclusion criteria: distant metastases.
Recruitment period: October 1990 to December 1997.
OC: 72/239 (30%).
OP: 98/239 (41%).
OC/OP: 170/239 (71%).
Number randomised: 243.
Number analysed: 239.
Interventions Hyperfractionated/accelerated radiotherapy versus conventional radiotherapy
Hyperfractionated/accelerated (vCHART) (n = 78): 2.5 Gy on day 1 as single fraction, then
16 consecutive days of 1.65 Gy twice daily with interfraction interval of ≥6 hours to a total
dose of 55.3 Gy. On weekdays therapy was performed with photons/electrons from a linear
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Dobrowsky 2000 (Continued)
accelerator, and on weekends and holidays a Cobalt-60 unit was used. Maximum dose to
spinal cord was 38.8 Gy
Conventional (n = 81): 70 Gy delivered in 35 fractions over 7 weeks, 5 fractions of 2 Gy/
week on weekdays using a linear accelerator to deliver photons & electrons. Maximum dose
to spinal cord was 46 Gy
Outcomes Primary: overall survival.
Secondary: locoregional response, recurrence, distant metastases, secondaries, toxicity
Duration of follow-up: median follow-up 48 months.
Notes Sample size calculation reported. It was calculated that a sample size of 324 patients would be
required to detect a ”difference in survival of 15% (from 25% to 40%) after 3 years between
2 of the treatment groups with a probability of 85% at a significance level of 0.05.“
The trial had a third treatment arm not used in this review as intervention under assessment
was chemotherapy not radiotherapy (V-CHART+MMC)
HR data taken from Kaplan-Meier graphs.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Patients were randomised by the Documen-
tation Office of the 1st Surgical University
Clinic“. Randomisation was stratified by site,
age, performance status & gender
Allocation concealment? Yes Allocation was made by telephone call to the
randomisation centre
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes All randomised patients included in the anal-
ysis.
Free of selective reporting? Yes Primary outcome of overall survival and sec-
ondary outcomes of toxicity, locoregional re-
sponse and recurrence
Free of other bias? Yes Groups appear similar at baseline. No other
apparent bias.
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Fu 1995
Methods Location of trial: US.
Number of centres: 5.
Funding: National Cancer Institute, National Institute of Health
Trial ID: RTOG 88-09.
Participants Inclusion criteria: Stage III or IV of oral cavity, oropharynx, supraglottic larynx or nasophar-
ynx, or Stage II, III, IV cancer of base of tongue or hypopharynx, age ≥ 18 years with Karnof-
sky performance status ≥ 60. No prior radiation therapy, chemotherapy or surgery
Exclusion criteria: prior or simultaneous malignancy, unless patient has been cancer free for
> 5 years, metastases below clavicle
Recruitment period: February 1989 to January 1990.
OC: 8/75 (11%).
OP: 38/75 (51%).
OC+OP: 46/75 (61%).
Number randomised: 75.
Number analysed: 70.
Interventions Hyperfractionated/accelerated split course radiotherapy versus accelerated radiotherapy
with concomitant boost
Hyperfractionated/accelerated/split course (AHFX-S) (n = 38): radiotherapy to primary tu-
mour and upper neck 1.6 Gy per fraction, twice daily with minimum 6-hour interfraction
interval, 5 times per week to a total dose of 38.4 Gy in 2.5 weeks. Rest from radiotherapy for
14 days then 1.6 Gy per fraction, twice daily to a reduced boost volume including primary
tumour and positive nodes to further 28.8 Gy. Total dose 67.2 Gy
Accelerated/ boost accelerated (AFX-C) Gr B (n = 32): 1.8 Gy per fraction, once daily, 5 times
per week to total dose of 54 Gy in 30 fractions over 6 weeks. During the last 11 days of basic
treatment a second daily dose of 1.5 Gy was given to a reduced boost volume. Total dose 70.
5 Gy
Outcomes Primary: locoregional control.
Secondary: overall survival, disease free survival, recurrence, toxicity
Duration of follow-up: median follow-up 2 years (0.03 to 4.87 years)
Notes Dichotomous data only; unable to calculate HR.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Stratified by Karnofsky performance status
(60-80 versus 90-100) and randomised“. No
details of sequence generation given but as-
sumed to be adequate as for other RTOG tri-
als
Allocation concealment? Yes Patients entered into study by a telephone call
to RTOG headquarters
Blinding - Outcome Assessors? No Not mentioned.
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Incomplete outcome data addressed? Unclear 5 patients excluded post-randomisation (1 in-
eligible due tometastasis, 1 hadpriorCT, 3 re-
fused treatment) but not ascribed to treatment
groups. Unclear from paper how many pa-
tients are included in percentage figures given
for locoregional control, disease free survival
and overall survival
Free of selective reporting? Yes Trial planned to report locoregional control
(success/failure) and tolerability and not pow-
ered for survival outcomes
Free of other bias? No Some imbalance between the groups at base-
line. The split course arm had higher percent-
age of OP primaries (63% versus 44%) and
Stage IV disease (82% versus 50%), and a
lower proportion of oral cavity lesions (3%
versus 22%) andN0 disease 16% versus 31%.
This imbalance has the potential to result in
bias in the outcomes locoregional control, dis-
ease free survival and overall survival
Fu 2000
Methods Location of trial: US, Canada.
Number of centres: > 40.
Funding: National Cancer Institute (grants CA21661, CA 37422, CA 32115, CA 06294)
Trial ID: RTOG 9003.
Participants Inclusion criteria: patients aged at least 18 years, with Karnofsky performance status ≥ 60%,
no prior treatment, with Stage II-IV disease M0 squamous cell carcinoma of oral cavity,
oropharynx or supraglottic larynx or Stage II-IV cancer of base of tongue or hypopharynx.
T1-T4 included
Exclusion criteria: prior or synchronous malignancy.
Recruitment period: September 1991 to August 1997.
OC: 110/1073 (10%).
OP: 649/1073 (60%).
OC+OP: 759/1073 (71%).
Number randomised: 1113.
Number analysed: 1073.
Interventions Hyperfractionated radiotherapy versus hyperfractionated/accelerated/split course radio-
therapy versus accelerated/boost radiotherapy versus conventional radiotherapy
Hyperfractionated (n = 263): 1.2 Gy per fraction, 2 fractions per day, interfraction interval 6
hours, 5 times per week to total dose of 81.6 Gy in 35 fractions over 7 weeks
Hyperfractionated/accelerated/split (n = 274): 1.6 Gy per fraction, 2 fractions per day, inter-
fraction interval 6 hours, 5 times per week to 38.4 Gy then 2 weeks rest then resume as for
Phase 1 with further 28.8 Gy for total of 67.2 Gy in 42 fractions over 6 weeks
Accelerated/boost (n = 268): 1.8 Gy per fraction, daily, interfraction interval 6 hours, 5 times
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per week together with a 1.5 Gy boost field for last 12 treatment days to a total of 72 Gy in
42 fractions over 6 weeks
Conventional (n = 268): 2 Gy per fraction, 5 fractions per week to a total of 70 Gy in 35
fractions over 7 weeks
Outcomes Primary: locoregional control at 2 years.
Secondary: overall survival, disease free survival, acute and late toxicity
Duration of follow-up: median follow-up was 23 months for all analysable patients and 41.
2 for surviving patients
Notes Sample size calculation. Study was designed to detect an increase in locoregional control from
40% to 55% with a type 1 error of 0.05 and power of 80%. Sample size was increased by
20% to allow for patients being found to be ineligible, lost to follow-up or dying without
locoregional failure within 2 years. Sample planned 1080 participants
Data from Kaplan-Meier graphs (numbers at risk presented).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Stratified by Karnofsky performance status
(90-100 versus 60-80), N stage (N+ ver-
sus N-) and primary site. Randomisation
was according to the scheme of Zelen, used
to achieve balance in treatment assignment
among the institutions
Allocation concealment? Yes Patientswere enrolled bymeans of a telephone
call to RTOG headquarters
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear 1113 patients randomised, 28 were found to
be ineligible, 5 refused protocol treatment or
died before treatment started, 7 had inade-
quate data, total 40/1113 = 4% excluded. Ex-
clusions not described by treatment group;
appears likely thatmore excluded fromhyper-
fractionated group (A) and fewer from split
accelerated group (B)
Free of selective reporting? Yes Important outcomes reported - locoregional
control, overall survival and disease free sur-
vival
Free of other bias? Unclear Appears to be some difference between groups
at baseline.
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Methods Location of trial: India.
Number of centres: 1.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: previously untreated patients with locally advanced squamous cell carci-
noma of oropharynx, hypopharynx & larynx, Stage III & IV, M0, aged > 25 years, Karnofsky
performance status ≥ 70, adequate haematological function, and no comorbidities
Exclusion criteria: large lymph nodes, extending beyond spinal cord where radiation therapy
to spare cord area would be difficult
Recruitment period: June 1998 to June 2004.
OC: 0/285 (0%).
OP: 186/285 (65%).
Number randomised: 290.
Number analysed: 285.
Interventions Accelerated fractionation with concomitant boost versus conventional fractionation ra-
diotherapy
Accelerated/boost (n = 145): 1.8 Gy per fraction 5 times per week for 5 weeks to a total of
45 Gy with additional 1.5 Gy fraction given daily after 6-hour interfraction interval for last
3 weeks for additional 22.5 Gy. Total dose 67.5 Gy
Conventional (n = 145): 2 Gy per fraction, 1 fraction per day, 5 times per week to a total
dose of 66 Gy over 6.5 weeks
Outcomes Primary: disease free survival.
Secondary: locoregional control, compliance with treatment protocol
Duration of follow-up: median duration of follow-up 2 years.
Notes ”Exploratory subgroup analyses were carried out on various prognostic variables.“
HR presented in text.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Permuted block randomisation using a com-
puter generated in house system. Randomisa-
tion was not stratified
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes 2 in each group did not receive treatment, 2
& 3 were lost to follow-up and 2 & 3 discon-
tinued treatment due to grade 3 mucositis.
Remainder were included in outcome evalu-
ation
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Free of selective reporting? Yes Disease free survival and locoregional control
were planned and reported
Free of other bias? Yes Groups appear comparable at baseline. No
other apparent bias
Griffin 1984
Methods Location of trial: USA
Number of centres: 2
Funding: not stated.
Trial ID: RTOG 7610a.
Participants Inclusion criteria: previously untreated histologically proven inoperable squamous cell carci-
noma, T2-4, anyN originating in oral cavity, oropharynx, supraglottic larynx or hypopharynx
Exclusion criteria: distant metastases, prior treatment for head & neck cancer
Recruitment period: February 1977 to April 1982.
OC: 10/40 (25%).
OP: 13/40 (33%).
OC+OP: 23/40 (58%).
Number randomised: 40.
Number analysed: 35.
Interventions Neutron versus photon
Neutron (n = 26): neutron dose equivalent to 66-74 Gy megavoltage photon irradiation
based on radiobiological effectiveness. Each fraction equivalent to 2.5 Gy photon irradiation
4 times per week. Uninvolved neck and supraclavicular region received equivalent of 46-50
Gy photon irradiation in neutrons. Duration of treatment was 7-8 weeks
Photon (n = 14): 66-74 Gy megavoltage photon irradiation in fractions of 1.8 to 2 Gy per
day, 5 fractions per week. Uninvolved neck and supraclavicular regions received 46-50 Gy
and duration of treatment was 7-8 weeks
Patients from both groups who had either residual or recurrent disease after RT were directed
to surgery if this was considered feasible
Outcomes Primary: unclear.
Locoregional control, overall survival, disease free survival
Duration of follow-up: minimum of 4 years.
Notes HR data taken from Kaplan-Meier graphs (no numbers at risk).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation stratified by region and stage
of primary tumour and institution where
treatment given. Randomised groups were
47Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Griffin 1984 (Continued)
”intentionally unbalanced“ to give a greater
proportion of patients in the mixed beam
group. Method of sequence generation not
described but assumed adequate as for other
RTOG trials
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear 5/40 excluded (3 from neutron group; 2 from
photon group) due to ineligibility or can-
celled. Unclear how many patients included
in outcome evaluation
Free of selective reporting? Yes Important outcomes of overall survival, lo-
coregional control and disease free survival
planned and reported
Free of other bias? Unclear Differences at baseline for age, gender andpri-
mary tumour.
Griffin 1989
Methods Location of trial: USA.
Number of centres: 5.
Funding: not stated.
Trial ID: RTOG 7610b.
Participants Inclusion criteria: previously untreated histologically proven inoperable squamous cell carci-
noma, T2-4, anyN originating in oral cavity, oropharynx, supraglottic larynx or hypopharynx
Exclusion criteria: distant metastases, Karnofsky performance status < 60, prior treatment for
head & neck cancer
Recruitment period: February 1977 to April 1982.
OC: 80/297 (27%).
OP: 154/297 (52%).
OC+OP: 234/297 (79%).
Number randomised: 327.
Number analysed: 297.
Interventions Neutron/photon mixed beam versus photon
Mixed beam (n = 163): combination of 40-44 Gy megavoltage photons and 7.5 to 10 Gy
neutrons, delivered as 3 fractions photons & 2 fractions neutrons per week. Each fraction 1.8
to 2 Gy or the equivalent based on the relative biological effectiveness of the neutron source.
Uninvolved neck and supraclavicular region received 46-50 Gy over 7-8 weeks
Photon (n = 134): 66-74 Gy megavoltage photon irradiation in fractions of 1.8 to 2 Gy per
day, 5 fractions per week. Uninvolved neck and supraclavicular regions received 46-50 Gy
and duration of treatment was 7-8 weeks
Patients from both groups who had either residual or recurrent disease after RT were directed
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to surgery if this was considered feasible
Outcomes Primary: tumour clearance rate.
Secondary: locoregional control, overall survival.
Duration of follow-up: minimum of 6 years.
Notes HR data taken from Kaplan-Meier graphs (no numbers at risk).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation stratified by region and stage
of primary tumour and institution where
treatment given. Randomised groups were
”intentionally unbalanced“ to give a greater
proportion of patients in the mixed beam
group. Method of sequence generation not
described but assumed adequate as for other
RTOG trials
Allocation concealment? Yes Eligible patients were randomised by means
of a phone call to the central office
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes After randomisation 16 patients were found
to be ineligible, 6 cancelled and 8 had inad-
equate data. Total of 15 patients per group
excluded for these reasons; unlikely to have
resulted in bias
Free of selective reporting? Unclear Main outcomes are reported but it is not clear
if the subgroup analyses were preplanned
Free of other bias? Yes Groups appear similar at baseline. No other
apparent bias.
Horiot 1992
Methods Location of trial: Europe.
Number of centres: 28.
Funding: not stated.
Trial ID: EORTC 22791.
Participants Inclusion criteria: patients aged ≤ 75 years, with Karnofsky performance status ≥ 60 who
have oropharyngeal cancer, T2 or T3, either N0 or N1 (providing there is a single node
involved and it is less than 3 cm)
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Exclusion criteria: lesions in the base of the tongue, whether N0 or N1 (< 3 cm)
Recruitment period: February 1980 to April 1987.
OP: 356/356 (100%).
Number randomised: 356.
Number analysed: 325.
Interventions Hyperfractionated radiotherapy versus conventional fractionation radiotherapy
Hyperfractionated (n = 166): 80.5 Gy in 70 fractions over 7 weeks. 2 fractions of 1.15 Gy
daily with interfraction interval of 4-6 hours
Conventional (n = 159): daily fraction of 1.75 to 2 Gy per fraction, to a total of 70 Gy in
35-40. Fractions over 7-8 weeks (the longer treatment time was used when large amounts of
mucosa within target volume)
Outcomes Primary: locoregional control.
Secondary: overall survival, tolerance, late toxicity.
Duration of follow-up: mean follow-up is 200 weeks, maximum follow up is 11 years
Notes HR data taken from Kaplan-Meier graphs (numbers at risk presented)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Randomised“. No further information re-
garding generation of random sequence pre-
sented
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear 29 patients (8%) found to be ineligible. Rea-
sons given in Table 3 but not per randomised
group. Seems likely that more were excluded
from conventional radiotherapy group and
that this may have introduced a bias
Free of selective reporting? Yes Important outcomes of locoregional control,
tolerance, survival and adverse effects re-
ported
Free of other bias? Unclear Little information presented on groups at
baseline.
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Methods Location of trial: 11 countries in Europe.
Number of centres: 26.
Funding: 4th Medical and Health Research Programme, concerted action 1989-92, Quality
Assurance in Cancer Clinical Research theme
Trial ID: EORTC 22851.
Participants Inclusion criteria: squamous cell carcinoma of head & neck, T2-T4. Patients aged ≤75 years,
with WHO performance status 0-2
Exclusion criteria: cancer of the hypopharynx.
Recruitment period: December 1985 to April 1995.
OC: 16%.
OP: 64%.
OC+OP: 80%.
Number randomised: 512.
Number analysed: 512.
Interventions Hyperfractionated/accelerated/split course radiotherapy versus conventional radiother-
apy
Hyperfractionated/accelerated/split (n = 257): Phase 1: 3 fractions of 1.6 Gy daily with
minimum 4-hour interfraction interval, for total of 28.8 Gy in 18 fractions over 8 days. 12-
14 day rest period
Phase 2: 43.2 Gy in 27 fractions of 1.6 Gy per fraction over 17 days starting on day 21. Total
dose of 72 Gy in 45 fractions over 5 weeks
Conventional (n = 255): 2 Gy per fraction, 1 fraction per day, 5 days per week to total of 70
Gy in 35 fractions over 7 weeks
In both groups the target volume was reduced once or twice after 50 Gy and spinal cord dose
remained less than 50 Gy. The boost techniques used in each institution varied according to
institution policy
Outcomes Primary: locoregional control.
Secondary: overall survival, disease specific survival, toxicity
Duration of follow-up: median duration of follow-up 4 years and 9 months
Notes Sample size calculation reported: ”Assuming a 2 year locoregional control rate of 35% in
the CF arm, it was estimated that 340 patients followed for 2 years .... would be enough to
detect a 15% difference in the 2 year LRC rates with an accuracy of 80% and a type 1 error
probability of 0.05.“ However, ”an excess of 172 patients was entered justified by the need to
increase the statistical power of a 10 year trial that would obviously be difficult to reproduce.
“
HR presented in text.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Randomisation performed centrally at the
EORTC data centre in Bristol“ Randomisa-
tion used the minimisation techniques and
was stratified by institution, site of primary
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tumour and stage (T2 versus T3-4)
Allocation concealment? Yes Allocation to treatment group obtained by a
telephone call to randomisation centre
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes 10/257 and 2/255 excluded from Gr A and
Gr B respectively, due to ineligibility. These
patients were included in the analysis
Free of selective reporting? Yes Important outcomes of locoregional control,
survival, time to progression and toxicity were
reported
Free of other bias? Yes Groups appear comparable at baseline. No
other apparent bias
Hukku 1991
Methods Location of trial: India.
Number of centres: 1.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: histologically proven squamous cell carcinoma, T3-4, N0-3, with primary
tumours in oral cavity, oropharynx, larynx and nasopharynx
Exclusion criteria: chronic medical problems and distant metastases
Recruitment period: January 1980 to August 1983.
OC: 7/110 (6%).
OP: 72/110 (65%).
OC+OP: 79/110 (70%).
Number randomised: 110.
Number analysed: 110.
Interventions Split course radiotherapy versus accelerated radiotherapy
Split course (n = 50): Phase 1: 15 fractions of 2.3 Gy over 3 weeks to primary tumour and
bilateral neck. 2-week break. Phase 2: 2.5 Gy per fraction for 10 fractions over 2 weeks to
primary tumour and residual lymphatic disease if present or upper neck if lymph nodes not
palpable
Conventional (n = 60): 4 Gy per fraction in 2 opposing fields, 5 fractions per week, total
of 11 fractions and 44 Gy. Treatment delivered to primary tumour along with bilateral neck
with reduction of neck field after 7 fractions
Outcomes Primary: locoregional control.
Secondary: overall survival, disease free survival, toxicity
Duration of follow-up: 2 years.
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Notes Dichotomous data only; unable to calculate HR.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Randomisation of patients...“. No details of
method of sequence generation provided
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes All randomised patients included in the out-
come analyses.
Free of selective reporting? Yes Important outcomes of overall survival, dis-
ease free survival, locoregional control and ad-
verse events reported
Free of other bias? Yes Groups appear similar at baseline. No other
apparent bias.
Inoue 2001
Methods Location of trial: Japan.
Number of centres: 1.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: patients with early mobile tongue cancer, T1-2, N0 which could be treated
with a single plane implantation, localisation of tumour at lateral border of the tongue, and
tumour thickness less that 10 mm, performance status 0-3
Exclusion criteria: any severe concurrent disease.
Recruitment period: April 1992 to October 1996.
OC: 59/59 (100%).
Number randomised: 59.
Number analysed: 51.
Interventions Low dose rate interstitial radiotherapy versus high dose rate interstitial radiotherapy
Low dose (n = 26): 0.30 to 0.93 Gy/h to total dose of 65-75 Gy (median 70 Gy) over 75 to
217 hours (median 117 hours)
High dose (n = 30): 0.99 to 4.1 Gy/min to total dose of 60 Gy in 10 fractions over 6-9 days
(median 7 days) with 2 fractions per day and interfraction interval of > 6 hours
Outcomes Primary: locoregional control.
Secondary: cause specific survival.
Duration of follow-up: minimum of 46 months (median duration of follow-up is 85 and 78
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months in the low dose and high dose groups respectively)
Notes HR data taken from Kaplan-Meier graphs (no numbers at risk).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Randomly allocated into LDR & HDR
groups according to Peto’s balanced randomi-
sation list.“
Allocation concealment? Unclear Not mentioned.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear 8 patients were excluded; 3 (10%) from low
dose rate and 5 (20%) from high dose rate
but reasons are not given for each treatment
group. This is a possible cause of bias
Free of selective reporting? Unclear Some important outcomes, locoregional con-
trol, survival and cause specific survival are re-
ported but there are no data on toxicity
Free of other bias? Unclear At baseline there is some difference between
groups with regard to tumour thickness. Low
dose rate group has more medium thickness
tumours and high dose rate more very thick
tumours. Tumour thickness is likely to be an
important prognostic factor linked to out-
come
Ketcham 1969
Methods Location of trial: US.
Number of centres: 1.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: squamous cell carcinoma of upper aerodigestive tract
Exclusion criteria: previous RT, recurrent disease, more than 1 primary lesion, cancer of the
lip. If the tumour was ”inadvertently cut across during surgery“ or if surgical margins were
positive, patient was excluded
Recruitment period: not stated.
OC: 44/79 (56%).
OP: unclear.
OC+OP: > 56%.
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Number randomised: unclear.
Number analysed: 79.
Interventions Pre-operative radiotherapy versus pre-operative sham radiotherapy
Pre-operative radiotherapy (n = 60): using a 2 MeV van der Graaf generator with output of
1 Gy per minute at 1 metre, a single dose of 10 Gy was administered over 15 minutes, 24
hours prior to surgery
Pre-operative sham radiotherapy (n = 19).
Outcomes Primary: surgical complications.
Secondary: locoregional control, metastases.
Duration of follow-up: 36-86 months.
Notes Dichotomous data only (unclear timing of outcome evaluation reported in paper); unable to
calculate HR
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Sealed envelope selected randomly from 3
groups based on type of surgery patient re-
quired.“ Not clear how the envelopes were
prepared
Allocation concealment? Yes Sealed envelope selected and taken by the pa-
tient to the radiotherapist, who opened it and
delivered either RTor shamdepending on en-
velope contents
Blinding - Outcome Assessors? Yes Double blinded - both the patient and the sur-
geon were blinded to the treatment. Surgeons
were asked to record whether they thought
each patient has had RT
Incomplete outcome data addressed? Unclear Unclear from the paper how many patients
in total were randomised, how many were
excluded post-randomisation and how many
were included in the outcome analyses
Free of selective reporting? Unclear Outcomes reported are surgical complica-
tions, recurrent disease andmetastases but not
survival, or numbers of patients who had pos-
itive margins or tumours inadvertently cut
Free of other bias? No Randomised treatment was pre-operative, yet
2 of the exclusion criteria related to the
surgery. It is possible that the large imbal-
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ance in number in the treatment and placebo
groups is related to surgical exclusions
Lawrence 1974
Methods Location of trial: US.
Number of centres: 1.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: previously untreated Stage II-IV squamous cell carcinoma of oral cavity,
oropharynx, or pharynx with technically resectable disease
Exclusion criteria: Stage I cancer (usually treated by radiation therapy alone), patients with
other cancers, including lip, paranasal sinus, nasopharynx, or glottic carcinoma of larynx
Recruitment period: January 1969 to December 1972.
OC: 64/143 (45%).
OP: 37/143 (26%).
OC+OP: 101/143 (71%).
Number randomised: 143.
Number analysed: 143.
Interventions Pre-operative radiotherapy plus surgery versus surgery alone
Pre-operative radiotherapy (n = 69): 2 fractions each of 1.4 Gy given 48 and 24 hours prior
to surgery. RT delivered by Co-60 unit using 80 cm source skin distance followed by radical
resection of primary carcinoma and simultaneous radical neck dissection
Surgery alone (n = 74): radical resection of primary carcinoma & simultaneous unilateral or
bilateral radical neck dissection
Outcomes Primary: surgical complications.
Secondary: overall survival, local recurrence.
Duration of follow-up: 4 years.
Notes Unable to use data.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Patients...randomly assigned“. Randomisa-
tion stratified by site of primary tumour and
stage of disease, but method of sequence gen-
eration not described
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
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Incomplete outcome data addressed? Yes All randomised patients are included in the
analyses.
Free of selective reporting? Yes Important outcomes of surgical complica-
tions, mortality and local recurrence reported
Free of other bias? Yes Groups appear comparable at baseline. No
other apparent bias
MacDougall 1990
Methods Location of trial: Edinburgh, Scotland.
Number of centres: 1.
Funding: Medical Research Council, Cancer Research Campaign, Scottish Home and Health
Department, Lothian Health Board
Trial ID: not stated.
Participants Inclusion criteria: previously untreated patients with histologically confirmed squamous cell
carcinoma of oral cavity, oropharynx, larynx or hypopharynx, less than 80 years old, deemed
fit for radiotherapy
Exclusion criteria: primary tumours with high probability of local control with photon treat-
ment
Recruitment period: 1977 to 1984.
OC: 66/165 (40%).
OP: 35/165 (21%).
OC+OP: 101/165 (61%).
Number randomised: 165.
Number analysed: 165.
Interventions Fast neutron radiotherapy versus photon radiotherapy
Fast neutron (n = 85): 20 daily fractions over 4 weeks. Total absorbed dose of 15.6 to 16.7
Gy
Photon (n = 80): 20 daily fractions over 4 weeks. Total absorbed dose 54-56 Gy
Outcomes Primary: locoregional control.
Secondary: 5 and 10 year survival, disease free survival at 5 years, cause specific survival, late
radiation necrosis
Duration of follow-up: minimum of 5 years, up to 11 years.
Notes Sample size calculation: based on predicted increase of locoregional control from 40% to 70%
it was estimated that 164 patients would be required to show this difference with power of
90% and α = 0.05 on a tow tailed test of significance
Part of multicentre trial but full data from 2 centres not available
Dichotomous data only for outcomes of interest.
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation stratified on site of primary
tumour and presence/absence of malignant
lymph nodes. Envelopes containing treat-
ment allocation prepared by trial statistician
in Edinburgh, and held by Neutron Clinic
secretary
Allocation concealment? Yes Sequentially numbered sealed envelopes were
drawn.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes All randomised patients included in analysis.
Free of selective reporting? Unclear No planned outcomes listed in methods sec-
tion. Important outcomes reported
Free of other bias? Unclear Gender imbalance between the groups, un-
clear if this would introduce a bias
Maor 1986
Methods Location of trial: US.
Number of centres: 4.
Funding: National Cancer Institute (core grant CA23113).
Trial ID: RTOG 7808.
Participants Inclusion criteria: untreated squamous cell carcinoma, T2-T4, with any N but M0. Patients
referred to trial following unsatisfactory response to initial radiotherapy
Exclusion criteria: more than 1 primary tumour or Karnofsky status < 50
Recruitment period: October 1978 to August 1982.
OC: 30/115 (26%).
OP: 59/115 (51%).
OC+OP: 89/115 (77%).
Number randomised: 118.
Number analysed: 115.
Interventions Neutron boost versus photon boost
Neutron boost (n = 57): to include only areas involved by gross tumour, primary, or nodes
plus a margin of 2 cm. Boost given in 4-6 fractions in 2-3 weeks. Neutron dose depended on
radiobiological effectiveness, equivalent to 25-30 Gy photons
Photon boost (n = 58): to include areas with gross tumour plus a 1 cm margin (2 cm with
cobalt). 25-30 Gy over 2-3 weeks in 5 daily fractions per week
All patients received 45-50 Gy photons in daily fractions of 1.8-2 Gy
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Outcomes Primary outcome unclear.
Tumour clearance, locoregional control, overall survival.
Notes Data taken from Kaplan-Meier graphs (no numbers at risk).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation stratified by institution, T
stage and region and performed by central of-
fice. No details given but assumed adequate
as for other RTOG trials
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes 3/118 excluded from the analysis. Unlikely to
affect results
Free of selective reporting? Yes Important outcomes of overall survival, local
clearance, locoregional control planned and
reported
Free of other bias? No 1 patient in neutron boost group and 5 in
photon boost group received interstitial im-
plants to deliver boost
Maor 1995
Methods Location of trial: US and UK.
Number of centres: 5 (4 US and 1 UK).
Funding: National Cancer Institute, Department of Health and Human Services (grants
CA06294, CA16672, CM57775) and Medical Research Council in UK
Trial ID: not stated.
Participants Inclusion criteria: patients with Stage III-IV tumours in the oral cavity, oropharynx, hy-
popharynx and larynx, T3-4 with any N or T2 with N > 1 or T1N3, Karnofsky performance
status > 60
Exclusion criteria: no distant metastases, no history of another cancer
Recruitment period: April 1986 to March 1991.
OC: 39/169 (23%).
OP: 87/169 (51%).
OC+OP: 126/169 (75%).
Number randomised: 178.
Number analysed: 169.
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Interventions Neutrons versus photons
Neutrons (n = 83): 20.4 Gy neutrons delivered in 12 fractions of 1.7 Gy over 4 weeks (3
fractions per week)
Photons (n = 86): 70 Gy of photons delivered in 35 fractions, 2 Gy per fraction over 7 weeks
(except in UK centre, 66 Gy in 30 fractions over 6 weeks)
Outcomes Primary: tumour clearance.
Secondary: locoregional control/relapse, overall survival, late toxicity
Duration of follow-up: median duration of follow-up 3.5 years (range 3 months to 6.7 years)
Notes HR data taken from Kaplan-Meier graphs (numbers at risk presented)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Patients...randomized to receive“. Details of
sequence generation not described. Stratifica-
tion by site and stage of primary tumour and
treating institution
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes 6/178 patients died before treatment started,
2had other cancers and1was lost to follow-up
(total 9 excluded 5% - reasons not described
by treatment group). All remaining patients
included in analyses
Free of selective reporting? Yes Important outcomes of locoregional control,
survival and toxicity reported
Free of other bias? Unclear Characteristics of the treatment groups at
baseline differed with regard to number of
patients with hypopharynx (more in photon
group) and supraglottic larynx (more in neu-
tron group). Paper states that this is likely to
meanmore patients in the neutron grouphave
worse prognosis
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Marcial 1987
Methods Location of trial: US.
Number of centres: unclear.
Funding: National Cancer Institute/National Institute for Health (grants CA12258,
CA32115, CA20235, CA21661)
Trial ID: RTOG 79-13.
Participants Inclusion criteria: advanced squamous cell carcinoma of oral cavity, pharynx, larynx and
paranasal sinus whose only planned therapy was radiation (with possible surgical salvage).
Patients had Stage III or IV tumours, or Stage II tumours of base of tongue, nasopharynx or
maxillary sinus. T1-T4 included
Exclusion criteria: metastatic disease, 2 primary tumours, previous chemotherapy or radio-
therapy or surgery, Karnofsky performance status < 60%
Recruitment period: August 1979 to June 1983.
OC: 28/187 (15%).
OP: 86/187 (46%).
OC+OP: 114/187 (61%).
Number randomised: 210.
Number analysed: 187.
Interventions Hyperfractionated/accelerated radiotherapy versus conventional radiotherapy
Hyperfractionated/accelerated (n = 94): 1.2 Gy per fraction, 10 fractions per week with
interfraction interval of 3-6 hours to total dose of 60 Gy over 5 weeks
Conventional (n = 93): 1.8 to 2 Gy per fraction, 5 fractions per week, to total dose of 66-73.
8 Gy over 7-8 weeks
Co-60 or higher energy used, dose specified tomid plane from parallel opposed fields covering
primary tumour and extensions with 1.5 cm margin. After 50 Gy lateral port was reduced to
cover primary tumour only
Outcomes Primary: tumour clearance.
Secondary: locoregional control, overall survival, early and late toxicity
Duration of follow-up: estimated to be 30 months.
Notes HR data taken from Kaplan-Meier graphs (no numbers at risk).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was undertaken at RTOG
headquarters in Philadelphia, and was strati-
fied by site of primary tumour and stage of dis-
ease. No details on method of sequence gen-
eration are provided but it is assumed to be
adequate
Allocation concealment? Yes Treatment allocation made by phone call to
RTOG headquarters
Blinding - Outcome Assessors? No Not mentioned.
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Incomplete outcome data addressed? Unclear 23 patients (11%) excluded. 10 were ineligi-
ble, 2 cancelled before treatment started and
11 had insufficient data. It is not stated which
treatment groups these patients are from, and
this may result in bias
Free of selective reporting? Yes Important outcomes of locoregional control,
survival and toxicity are reported
Free of other bias? No Groups are not balanced at baseline in the
distributionofKarnofsky performance scores,
which are likely to be linked with prognosis.
Randomisation was not stratified by treating
institution
Marcial 1993
Methods Location of trial: US.
Number of centres: approximately 7.
Funding: National Cancer Institute (grants CA12258 and CA32115)
Trial ID: RTOG trial (number unclear).
Participants Inclusion criteria: patients with all stages of untreated cancer of the tonsillar fossa
Exclusion criteria: patients aged > 80 years, with adenocarcinoma, other cancers (previous
or present except for skin cancers), presence of distant metastases, medical conditions which
made treatment completion unlikely, or patient deemed unlikely to complete follow-up
Recruitment period: 1971 to 1976.
OP: 147/147 (100%).
Number randomised: 147.
Number analysed: 137.
Interventions Accelerated split course radiotherapy versus continuous radiotherapy
Split course (n = 63): Phase 1: 3 Gy per fraction, 10 fractions over 2 weeks total of 30 Gy. 3
weeks rest. Phase 2: 3 Gy per fraction and further 10 fractions over 2 weeks
Continuous (n = 74): 2.0-2.2 Gy per fraction, with 30-33 fractions over 6 weeks to a total
dose of 66 Gy. Original protocol was modified to allow 2 Gy fractions to a total of 60-66 Gy
Spinal cord protection was required after 50 Gy in Phase 2. Source was teletherapy energy at
1 MeV or higher with minimal source skin distance of 75 cm. Surgical salvage was permitted
at least 2 months after completion of radiotherapy
Outcomes Primary: tumour clearance.
Secondary: locoregional control, overall survival, acute and late toxicity
Duration of follow-up: minimum of 7 years (4% of patients lost to follow-up prior to 7 years)
Notes Dichotomous data only; unable to calculate HR. Locoregional control data presented as
percentage but unclear of denominator
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation done at RTOG headquarters
in Philadelphia and was stratified by institu-
tion, T stage, N stage and gender. No details
on method of sequence generation provided
but it is assumed to be adequate
Allocation concealment? Yes Treatment allocation made by telephone call
to RTOG headquarters
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear 10 patients (7%) excluded. 17 reasons for ex-
clusions (3 cancellation, 3 ineligible, 11 no
data) for 10 people - unclear how many and
which treatment group they were from
Free of selective reporting? Yes Important outcomes of tumour response, lo-
coregional control, overall survival and toxic-
ity reported
Free of other bias? Yes No significant differences between the groups
at baseline. No other apparent bias
Olmi 2003
Methods Location of trial: Italy.
Number of centres: 18.
Funding: Consiglio Nazionale delle Richerche.
Trial ID: ORO-93 01.
Participants Inclusion criteria: histologically proven squamous cell carcinoma of oropharynx, Stage III or
IV, M0 no prior surgery, radiotherapy or chemotherapy, age < 70 years, Karnofsky perfor-
mance status ≥70 or ECOG 0-2, adequate bone marrow reserve, renal, hepatic cardiac and
pulmonary function, available for follow-up, informed consent
Exclusion criteria: T1N1 & T2N1, previous tumours, active infectious disease, psychosis
Recruitment period: January 1993 to June 1998.
OP: 192/192 (100%).
Number randomised: 192.
Number analysed: 182.
Interventions Conventional radiotherapy plus concomitant chemotherapy versus hyperfractionated/
accelerated/split course radiotherapy versus conventional radiotherapy
Conventional radiotherapy plus concomitant chemotherapy (n = 64): 66-70 Gy in 33-35
fractions (2 Gy/fraction) 5 times per week over 6.5 to 7 weeks. 50 Gy to uninvolved neck
nodes, tolerance dose for spinal cord 44 Gy. Carboplatin 75 mg/m2 IV over 30 minutes on
days 1-4 of RT, and 5FU 1000 mg/m2/day IV continuous over 96 hours on days 1-4, repeated
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on weeks 5 and 9 of RT
Hyperfractionated/accelerated/split (n = 65): 64-67.2 Gy - 2 fractions each of 1.6 Gy daily
with 4-6 hour interfraction interval, 5 times per week. After 38.4 Gy over 2 weeks 2-week
split planned, followed by a repeat of phase 1
Conventional (n = 63): 66-70 Gy in 33-35 fractions (2 Gy/fraction) 5 times per week over
6.5 to 7 weeks. 50 Gy to uninvolved neck nodes, tolerance dose for spinal cord 44 Gy
Outcomes Primary: survival at 5 years.
Secondary: overall survival, relapse free survival, locoregional control, acute and late toxicity
Duration of follow-up: median follow-up 8.35 years (4.8 to 10.2 years)
Notes Trial closed prior to planned accrual of 260 due to slowed accrual rate
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation performed by the Instituto
Mario Negri, Milan. Patients were stratified
by centre and disease stage (Stage III & IV
N0-N1 versus Stage IV N2-3). No details on
sequence generation given
Allocation concealment? Unclear Insufficient information.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes 10 patients are excluded from analysis (across
groups), 8 of these are due to death during
treatment, reasons for other unclear. Unlikely
to have introduced bias to results
Free of selective reporting? Yes Important outcomes of locoregional control,
mortality, acute and late toxicity reported
Free of other bias? Yes Groups appear similar at baseline. No other
apparent bias.
Pinto 1991
Methods Location of trial: Brazil.
Number of centres: 1.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: patientswith previously untreated, histopathologically confirmed squamous
cell carcinoma, Stage III & IV oropharyngeal cancer, aged < 70, no previous malignancy
(except basal cell carcinoma of skin), no trismus, no metastases and Karnofsky performance
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status ≥ 50%
Exclusion criteria: not explicitly stated.
Recruitment period: April 1986 to May 1989.
OP: 112/112 (100%).
Number randomised: 112.
Number analysed: 98.
Interventions Hyperfractionated radiotherapy versus conventional radiotherapy
Hyperfractionated (n = 56): 64 fractions of 1.1 Gy given twice daily to a total dose of 70.4
Gy over 6.5 weeks with minimum interfraction interval of 6 hours
Conventional (n = 54): 33 fractions of 2 Gy per fractions given 5 times per week over 6.5
weeks to total dose of 66 Gy
The spinal cord was protected after 46.2 Gy and 46 Gy in the hyperfractionated and conven-
tional groups respectively. Radiation delivered from Co-60 machine at distance of 80 cm
Outcomes Primary: overall survival.
Secondary: locoregional control, early and late toxicity.
Duration of follow-up: median follow-up 22.5 months (7-41 months)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”...randomly allocated .... after stratification
by site of primary tumour, T stage (T1-2 vs
T3-4) N stage (N0 vsN1 vs N2-3) and lymph
node size (> or <6 cm)“.Nodetails onmethod
of sequence generation provided
Allocation concealment? Unclear Not mentioned.
Blinding - Outcome Assessors? Unclear Assessment of late radiation induced fibrosis
conducted by clinician blinded to treatment
allocation
Incomplete outcome data addressed? Yes 14 patients (12%) excluded from the analy-
ses. In hyperfractionated group 2 died dur-
ing treatment and 4 stopped treatment early
and in conventional RT group 3 died and 5
stopped treatment early. This is unlikely to
have resulted in bias
Free of selective reporting? Yes Important outcomes of overall survival, lo-
coregional control and toxicity reported
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Free of other bias? Yes Groups well balanced at baseline for main
prognostic factors
Poulsen 2001
Methods Location of trial: Australia and New Zealand.
Number of centres: 14.
Funding: Queensland Cancer Fund.
Trial ID: not stated.
Participants Inclusion criteria: invasive squamous cell carcinoma in oral cavity, oropharynx, hypopharynx
or larynx, disease at Stage III or IV, ECOG performance status 0-2, age ≤ 80 years, weight >
40 kg, loss of body weight < 15%
Exclusion criteria: prior radiotherapy, chemotherapy, or therapeutic surgery, other active ma-
lignancy, intercurrent illness likely to reduce life expectancy or exacerbate toxicity
Recruitment period: 1991 to 1998.
OC: 37/343 (11%).
OP: 229/343 (67%).
OC+OP: 266/343 (78%).
Number randomised: 350.
Number analysed: 343.
Interventions Hyperfractionated/accelerated radiotherapy versus conventional radiotherapy
Hyperfractionated/accelerated (n = 172): 1.8 Gy per fraction twice daily to a dose of 39.6
Gy in 22 fractions over 16 days with macroscopic disease receiving a dose of 59.4 Gy in 33
fractions over 24 days. Spinal cord dose was initially limited to 42 Gy but this was decreased
to 40 Gy after a case of myelitis
Conventional (n = 171): large volume comprising primary site and all draining lymph nodes
at risk were treated with 2Gy per fraction 5 fractions per week to total of 50 Gy in 25 fractions
over 35 days. Macroscopic disease with 1 cm margin was boosted to 70 Gy in 35 fractions
over 49 days. Spinal cord dose was limited to 45 Gy
Outcomes Primary: disease free survival at 5 years.
Secondary: disease specific survival, locoregional control, toxicity
Duration of follow-up: median 53 months (14-101 months).
Notes Sample size: estimated that 342 patients were required to enable a difference of 15% in disease
free survival from 40% to 55% to be detected with 80% power at 5% level of significance
using a 2-sided test
HR presented in text.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation done by Data Management
Office of Queensland Radium Institute, strat-
ified by primary tumour site and stage (4
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groups). No details of themethod of sequence
generation provided but assumed to be ade-
quate
Allocation concealment? Yes Allocation made by telephone call to ran-
domisation centre.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes 7 (2%) patients excluded from analysis: 3
refused treatment, 3 found to be ineligible,
1 died before treatment started. Not stated
which groups these were from but numbers
small and unlikely to have introduced a bias
Free of selective reporting? Yes Important outcomes of disease free survival,
survival, locoregional control and toxicity
were reported
Free of other bias? Yes Authors state that groups were comparable at
baseline for the variables examined
Sanguineti 2005
Methods Location of trial: Italy.
Number of centres: 4.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: pathologically proven squamous cell carcinoma of the oral cavity, orophar-
ynx, hypopharynx or larynx, and major surgical resection of primary disease and clinically
involved neck lymph nodes without macroscopic residual; ECOG performance status ≤ 2
before radiotherapy, no distant metastases
Exclusion criteria: patients with other concurrent or previous (within 5 years) cancers other
than basal cell carcinoma of the skin and in situ squamous cell carcinoma of the cervix
Recruitment period: March 1994 to August 2000.
OC: 44/226 (19%).
OP: 40/226 (18%).
OC+OP: 84/226 (37%) (see notes).
Number randomised: 226.
Number analysed: 226.
Interventions Accelerated radiotherapy with boost versus conventional radiotherapy
Accelerated/boost (n = 113 (46 OC/OP patients)): 2 Gy/fraction, 5 fractions a week for 5
weeks. A concomitant boost of 1.4 Gy/fraction during first week and 1.6 Gy/fraction during
fifth week of radiotherapy was given (total dose 64 Gy)
Conventional (n = 113 (38 OC/OP patients)): 2 Gy/fraction, 5 fractions a week for 5 weeks
(total 50 Gy) to areas at low risk of macroscopic disease and 6 weeks (total 60 Gy) to areas at
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high risk
All radiotherapy had to commence within 8 weeks following surgery. Surgery consisted of
major surgical resection of both primary disease and clinically involved neck lymph nodes
without macroscopic residual
Outcomes Primary: locoregional control.
Secondary: overall survival, toxicity.
Duration of follow-up: 10 years.
Notes Sample size: estimated that 224 patients would provide power of 80% (with an α error of
5%, 2-sided) to detect improvement of 81% in the probability of locoregional control at 2
years in the accelerated radiotherapy group compared with 70% in the conventional group
HR calculated for OC/OP patients only using data supplied by authors
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Computer generated list and stratified ac-
cording to center and balanced by variable
blocks.“
Allocation concealment? Yes ”A centralized telephone call procedure to
the unit of clinical epidemiology and trials in
Genoa.“
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes All randomised participants included in anal-
ysis for locoregional control and overall sur-
vival. For acute toxicity 221/226 participants
analysed and for late toxicity 214/226 partic-
ipants analysed
Free of selective reporting? Yes Important outcomes of overall survival, lo-
coregional control and toxicity were reported
Free of other bias? Unclear Groups appear similar at baseline. No other
apparent bias.
Skladowski 2006
Methods Location of trial: Poland.
Number of centres: 1.
Funding: Polish Scientific Research Committee (grant #4PO5 B15208)
Trial ID: not stated.
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Participants Inclusion criteria: histologically proven squamous cell carcinoma with primary tumour in
oropharynx, hypopharynx oral cavity or supraglottic larynx, T2-4, N0-1, aged ≤ 70 years,
WHO performance status ≤ 2 and no other neoplastic disorders
Exclusion criteria: weight loss more than 10% in past 3 months, radiologically confirmed
infiltration of mandible or thyroid cartridge or refusal
Recruitment period: December 1993 to June 1996.
OC: 22/100 (22%).
OP: 28/100 (28%).
OC+OP: 50/100 (50%).
Number randomised: 100.
Number analysed: 100.
Interventions Accelerated radiotherapy versus conventional radiotherapy
Accelerated (n = 51): 2 Gy per fraction, 7 daily fractions per week to total of 66 Gy ± 2 Gy for
T2, & 70 Gy ± 2 Gy for T3-4 with overall treatment time of 33-36 days. Large fields covering
the whole clinical target volume were used Monday to Friday and at weekends a smaller field,
limited to primary tumour and involved nodes only, was irradiated. Patients were hospitalised
for the duration of the treatment
Conventional (n = 49): 2 Gy per day, 5 times per week, to a total of 66 Gy ± 2 Gy for T2 and
70 Gy ± 2 Gy for T3-4 with overall treatment time of 47-50 days. Small fields were used as a
shrinking fields technique during last week of treatment
From 1995 the fraction size was changed from 2 Gy to 1.8 Gy in both arms ”due to the high
rate of mucosal necrosis.“
Outcomes Primary: local tumour control.
Secondary: overall survival, morbidity free survival, disease free survival, acute and late toxicity
Duration of follow-up: median follow-up 96 months (59-123 months)
Notes Sample size calculation: to detect an expected increase in local tumour control in the CAIR
arm of 24% it was estimated that about 200 patients were required with α = 0.05 and 1-β =
0.90 (2-sided test). Investigators planned an interim analysis and possible change to protocol,
to detect unacceptable treatment toxicity, or unexpectedly high benefit
HR data taken from graphs (no numbers at risk).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Simple randomisation stratified by site of
primary tumour, TNM Stage with 1:1 arm
allocation, was made at Bureau of Trials at the
Instiute using random numbers.“
Allocation concealment? Yes Sealed envelope method used.
Blinding - Outcome Assessors? No Not mentioned.
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Incomplete outcome data addressed? Yes No drop outs post-randomisation. 2 in accel-
erated group and 1 in conventional group did
not complete treatment
Free of selective reporting? Yes Important outcomes of response, survival and
toxicity reported
Free of other bias? Unclear Fraction size reduced in both groups from 2
Gy to 1.8 Gy in 1995 in response to planned
interim analysis. Accelerated group were hos-
pitalised throughout treatment and received a
higher rate of systemic corticosteroids and/or
antibiotics for severe mucositis - 90% com-
pared to 48% in control group
Terz 1981
Methods Location of trial: USA.
Number of centres: 2.
Funding: not stated.
Trial ID: not stated.
Participants Inclusion criteria: previously untreated squamous cell carcinoma Stages II-IV of oral cavity,
oropharynx or hypopharynx if disease appeared to be technically resectable
Exclusion criteria: Stage 1 disease, patients with primary tumours of lip, nasopharynx,
paranasal sinuses or larynx
Recruitment period: January 1969 to September 1975.
OC: 94/248 (38%).
OP: 72/248 (29%).
OC+OP: 166/248 (67%).
Number randomised: 248.
Number analysed: unclear.
Interventions Pre-operative radiotherapy versus surgery alone
Pre-operative radiotherapy (n = 126): 1.4 Gy in 2 equal fractions 48 and 24 hours prior to
surgery. Radiotherapy administered through a pair of opposed fields to cover both primary
lesion and entire cervical lymph drainage area. Co-60 source with source to skin = 80 cm.
Followed by resection of primary tumour with uni or bilateral neck dissection
Surgery alone (n = 122): resection of primary tumour with uni or bilateral neck dissection
Outcomes Primary: complications, operative mortality.
Secondary: recurrence, 5-year disease free survival.
Duration of follow-up: 4-9 years.
Notes HR taken from Kaplan-Meier graph (no numbers at risk).
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Unclear No details on method of sequence generation
used. Randomisation was stratified on site of
primary tumour and stage of disease
Allocation concealment? Unclear Not mentioned.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Unclear Unclear how many patients are included in
the analysis as only percentages are reported
Free of selective reporting? Unclear Many outcomes reported - complications, op-
erativemortality, locoregional recurrence, dis-
ease free survival. Subgroup analyses were also
undertaken and it is not clear if these were
preplanned
Free of other bias? Yes Groups appear similar at baseline. No other
apparent bias.
Weissberg 1983
Methods Location of trial: US.
Number of centres: 1.
Funding: US Public Health Service (grant CA 06519).
Trial ID: not stated.
Participants Inclusion criteria: inoperable advanced biopsy proven squamous cell carcinoma of head and
neck
Exclusion criteria: metastatic disease beyond neck nodes, Karnofsky performance status <
60%, other malignant neoplasms in past 5 years
Recruitment period: 1973 to 1979.
OC: 12/64 (19%).
OP: 29/64 (45%).
OC+OP: 41/64 (64%).
Number randomised: 64.
Number analysed: 56.
Interventions Accelerated radiotherapy versus conventional radiotherapy
Accelerated (n = 33): high fractional dose of 4 Gy per day to total dose of 40-48 Gy in 2-3
weeks. Bilateral neck regions irradiated to 28 Gy and spinal cord dose limited to 28 Gy
Conventional (n = 31): 2 Gy per day to total of 60-70 Gy over 6-7 weeks. Bilateral neck
regions irradiated to 44 Gy and spinal cord dose limited to 44 Gy
Radiotherapy from 2 MeV van der Graff generator or 4 or 6 MeV linear accelerator
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Outcomes Primary: disease free survival at 5 years.
Secondary: disease free survival, regression, toxicity.
Duration of follow-up: 5-7 years.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Randomized“ but no details on method of
sequence generation used
Allocation concealment? Unclear Not mentioned.
Blinding - Outcome Assessors? No Not mentioned.
Incomplete outcome data addressed? Yes Gr A 1 patient withdrew and 2 died dur-
ing treatment; Gr B 3 died during treatment,
1 stroke and 1 withdrew due to metastatic
disease. Total 13% post-randomisation exclu-
sion but numbers and reasons similar in each
group
Free of selective reporting? Yes Tumour regression, survival and toxicity re-
ported.
Free of other bias? Unclear Imbalance between groups with regard to
oral cancer primaries (10 versus 2). Unclear
whether this indicates bias
CT = chemotherapy; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organisation for Research and Treatment
of Cancer; HR = hazard ratio; N = node; OC = oral cavity; OP = oropharynx; RT = radiotherapy; RTOG = Radiation Therapy
Oncology Group; T = tumour; WHO = World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arimoto 2003 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Awwad 1992 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Awwad 2002 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
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Baumann 2001 2 commentaries on Fu 2000; no additional data.
Catterall 1977 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
CHART 1997 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Cummings 2007 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
DAHANCA 2003 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Datta 1989 Abstract only. No subsequent publication identified. Unclear percentage of oral cavity and oropharyngeal cancer
patients included
Dieckmann 1990 Uncertain if truly randomised - abstract only, no subsequent publication identified
Dvivedi 1978 59% of patients have squamous cell carcinoma of the head and neck but not stated how many of these have
oral cavity or oropharyngeal cancer. No longer possible to contact authors
Flores 1996 Unclear how many of these have oral cavity or oropharyngeal cancer
Garden 2004 3 treatment groups, each with different chemotherapy regimen, therefore results cannot be attributed to radio-
therapy
Giglio 1997 Comparison of radiotherapy regimen, but results confounded by use of chemotherapy in 1 arm
Hansen 1997 Reanalysis of data from 2 DAHANCA studies.
Hering 1981 Randomisation not mentioned.
Hintz 1979 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Holsti 1988 Inadequate randomisation - odd versus even birth dates.
Jackson 1997 Some trial participants are randomly allocated to treatment, and some are not. Minority of participants have
oral cavity or oropharyngeal cancer. Attempts to contact author failed
Janot 2008 Patients had recurrent disease.
Johnson 1995 Conference abstract. No information on proportion of included participants with oral cavity or oropharyngeal
cancer. No subsequent publication identified
Katori 2007 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Klima 1988 Patients with metastatic disease included.
Kokal 1988 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
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Kramer 1987 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Maor 1983 Includes recurrent cancer patients.
Mishra 1996 Only some of the patients are randomised but all are analysed together. ”However some surgeons preferred to
put more clinically node-positive cases into the post-operative radiotherapy group.“
Nissenbaum 1984 Less than 6 months follow-up.
Noel 1997 Unclear how many patients have oral cavity or oropharyngeal cancer
Noel 1997a Unclear how many patients have oral cavity or oropharyngeal cancer
Noel 1997b Unclear how many patients have oral cavity or oropharyngeal cancer
Noel 2001 Commentary on 4 trials - no data.
Rink 1989 3 groups but not randomised.
Robertson 1998 Comparison of 2 different radiotherapy regimens, 1 of which includes surgery. Results confounded
Sanchiz 1990 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Singh 1984 Unclear if true RCT. Data presented as percentages; unclear denominator
Snow 1981 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer. Authors have not responded to
request for separate data
Srivastava 2001 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Strong 1978 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Suwinski 2008 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Tupchong 1991 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
RCT = randomised controlled trial.
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Characteristics of studies awaiting assessment [ordered by study ID]
Ang 2007
Methods
Participants
Interventions
Outcomes
Notes Abstract only - full text due maybe in 2010.
Ghosh 2006
Methods
Participants
Interventions
Outcomes
Notes Abstract only - awaiting full paper.
Nutting 2009a
Methods PARSPORT study.
Participants
Interventions
Outcomes
Notes American Society of Clinical Oncology (ASCO) abstract 2009 - outcome = xerostomia, full report due in 2010 or
2011
Rodrigo 2004
Methods Randomised controlled trial.
Participants Head and neck cancer patients.
Interventions Post-operative radiotherapy versus surgery.
Outcomes Total mortality, disease specific survival, locoregional control
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Notes Awaiting translation.
Rosenthal 2006
Methods
Participants
Interventions
Outcomes
Notes Abstract only - unclear of oral cavity/oropharyngeal percentages in full group
Skladowski 2001
Methods Randomised controlled trial.
Participants Head and neck cancer patients (oral cavity, oro-hypopharynx and larynx in Stage T2-4, N0-1, M0)
Interventions 7 fractions in 7 days versus 7 fractions in 5 days.
Outcomes Toxicity (additional outcomes unclear).
Notes Information taken from published abstracts.
Characteristics of ongoing studies [ordered by study ID]
Moergel 2009
Trial name or title
Methods Non-blinded, multicentre randomised controlled trial.
Participants Histologically verified diagnosis of a primary squamous cell carcinoma of the oral cavity or the oropharynx
are eligible
”- Maximum tumor diameter less than 4 cm in the pathohistological specimen irrespective of histological
grading (pT1 or pT2)
- Concomitant histological verification of a singular ipsilateral lymph node metastasis less than 3 cm in
diameter (pN1) without penetration of the lymph node’s capsule and without presence of lymphangiosis
carcinomatosa
- Radical resection of the tumor within adequate resection margins (R0)
- Written informed consent from the patient
- Adequate performance status ECOG Index greater or equal to 2
Patients younger than 18 and pregnant women are to be excluded.“
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Moergel 2009 (Continued)
Interventions Surgery plus radiotherapy versus surgery alone.
Outcomes Primary outcome: overall survival.
Secondary outcomes: incidence and time to tumour relapse, quality of life and time from surgery to orofacial
rehabilitation
Starting date September 2009.
Contact information Maximilian Moergel (moergel@mkg.klinik.uni-mainz.de).
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Altered fractionation versus conventional radiotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality (using IPD
where available)
13 Hazard Ratio (Fixed, 95% CI) 0.88 [0.82, 0.95]
1.1 Hyperfractionated versus
conventional
3 Hazard Ratio (Fixed, 95% CI) 0.78 [0.68, 0.90]
1.2
Hyperfractionated/accelerated
versus conventional
4 Hazard Ratio (Fixed, 95% CI) 0.87 [0.75, 1.00]
1.3 Hyperfractionated/
accelerated/split versus
conventional
4 Hazard Ratio (Fixed, 95% CI) 1.02 [0.90, 1.17]
1.4 Accelerated versus
conventional
1 Hazard Ratio (Fixed, 95% CI) 0.27 [0.16, 0.47]
1.5 Accelerated/boost versus
conventional
3 Hazard Ratio (Fixed, 95% CI) 0.95 [0.80, 1.13]
2 Locoregional control (using IPD
where available)
11 Hazard Ratio (Fixed, 95% CI) 0.80 [0.73, 0.87]
2.1 Hyperfractionated versus
conventional
3 Hazard Ratio (Fixed, 95% CI) 0.74 [0.62, 0.89]
2.2
Hyperfractionated/accelerated
versus conventional
4 Hazard Ratio (Fixed, 95% CI) 0.84 [0.72, 0.99]
2.3 Hyperfractionated/
accelerated/split versus
conventional
4 Hazard Ratio (Fixed, 95% CI) 0.86 [0.74, 1.01]
2.4 Accelerated versus
conventional
1 Hazard Ratio (Fixed, 95% CI) 0.26 [0.14, 0.50]
2.5 Accelerated/boost versus
conventional
1 Hazard Ratio (Fixed, 95% CI) 0.78 [0.62, 0.99]
3 Disease free survival 8 Hazard Ratio (Fixed, 95% CI) 0.88 [0.80, 0.96]
3.1 Hyperfractionated versus
conventional
1 Hazard Ratio (Fixed, 95% CI) 0.88 [0.72, 1.07]
3.2
Hyperfractionated/accelerated
versus conventional
1 Hazard Ratio (Fixed, 95% CI) 0.87 [0.66, 1.14]
3.3 Hyperfractionated/
accelerated/split versus
conventional
2 Hazard Ratio (Fixed, 95% CI) 1.04 [0.88, 1.24]
3.4 Accelerated versus
conventional
2 Hazard Ratio (Fixed, 95% CI) 0.68 [0.51, 0.91]
3.5 Accelerated/boost versus
conventional
4 Hazard Ratio (Fixed, 95% CI) 0.82 [0.69, 0.96]
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Comparison 2. Summary analyses for altered fractionation versus conventional radiotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 13 Hazard Ratio (Random, 95% CI) 0.86 [0.76, 0.98]
2 Locoregional control 11 Hazard Ratio (Random, 95% CI) 0.79 [0.70, 0.89]
3 Disease free survival 8 Hazard Ratio (Random, 95% CI) 0.85 [0.70, 1.03]
Comparison 3. Neutron therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 4 Hazard Ratio (Fixed, 95% CI) 1.11 [0.96, 1.27]
1.1 Mixed beam
(neutron/photon) versus
photon
1 Hazard Ratio (Fixed, 95% CI) 1.12 [0.92, 1.36]
1.2 Neutron versus photon 3 Hazard Ratio (Fixed, 95% CI) 1.10 [0.90, 1.34]
79Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Altered fractionation versus conventional radiotherapy, Outcome 1 Total
mortality (using IPD where available).
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy
Comparison: 1 Altered fractionation versus conventional radiotherapy
Outcome: 1 Total mortality (using IPD where available)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hyperfractionated versus conventional
Fu 2000 -0.17 (0.1) 13.8 % 0.84 [ 0.69, 1.03 ]
Horiot 1992 -0.27 (0.12) 9.6 % 0.76 [ 0.60, 0.97 ]
Pinto 1991 -0.56 (0.22) 2.8 % 0.57 [ 0.37, 0.88 ]
Subtotal (95% CI) 26.2 % 0.78 [ 0.68, 0.90 ]
Heterogeneity: Chi2 = 2.65, df = 2 (P = 0.27); I2 =25%
Test for overall effect: Z = 3.43 (P = 0.00060)
2 Hyperfractionated/accelerated versus conventional
Bourhis 2006 -0.2 (0.14) 7.0 % 0.82 [ 0.62, 1.08 ]
Dobrowsky 2000 -0.1 (0.18) 4.3 % 0.90 [ 0.64, 1.29 ]
Marcial 1987 -0.07 (0.15) 6.1 % 0.93 [ 0.69, 1.25 ]
Poulsen 2001 -0.18 (0.14) 7.0 % 0.84 [ 0.63, 1.10 ]
Subtotal (95% CI) 24.5 % 0.87 [ 0.75, 1.00 ]
Heterogeneity: Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
3 Hyperfractionated/accelerated/split versus conventional
Bartelink 2002 0.1 (0.32) 1.3 % 1.11 [ 0.59, 2.07 ]
Fu 2000 0.01 (0.1) 13.8 % 1.01 [ 0.83, 1.23 ]
Horiot 1997 -0.02 (0.11) 11.4 % 0.98 [ 0.79, 1.22 ]
Olmi 2003 0.2 (0.2) 3.4 % 1.22 [ 0.83, 1.81 ]
Subtotal (95% CI) 30.0 % 1.02 [ 0.90, 1.17 ]
Heterogeneity: Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
4 Accelerated versus conventional
Skladowski 2006 -1.31 (0.28) 1.8 % 0.27 [ 0.16, 0.47 ]
Subtotal (95% CI) 1.8 % 0.27 [ 0.16, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.68 (P < 0.00001)
5 Accelerated/boost versus conventional
Ang 2001 0.39 (0.26) 2.0 % 1.48 [ 0.89, 2.46 ]
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
(Continued . . . )
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Fu 2000 -0.09 (0.1) 13.8 % 0.91 [ 0.75, 1.11 ]
Sanguineti 2005 -0.29 (0.28) 1.8 % 0.75 [ 0.43, 1.30 ]
Subtotal (95% CI) 17.6 % 0.95 [ 0.80, 1.13 ]
Heterogeneity: Chi2 = 3.76, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 100.0 % 0.88 [ 0.82, 0.95 ]
Heterogeneity: Chi2 = 34.34, df = 14 (P = 0.002); I2 =59%
Test for overall effect: Z = 3.39 (P = 0.00071)
Test for subgroup differences: Chi2 = 26.39, df = 4 (P = 0.00), I2 =85%
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
Analysis 1.2. Comparison 1 Altered fractionation versus conventional radiotherapy, Outcome 2
Locoregional control (using IPD where available).
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy
Comparison: 1 Altered fractionation versus conventional radiotherapy
Outcome: 2 Locoregional control (using IPD where available)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hyperfractionated versus conventional
Fu 2000 -0.25 (0.12) 13.6 % 0.78 [ 0.62, 0.99 ]
Horiot 1992 -0.39 (0.15) 8.7 % 0.68 [ 0.50, 0.91 ]
Pinto 1991 -0.17 (0.35) 1.6 % 0.84 [ 0.42, 1.68 ]
Subtotal (95% CI) 23.9 % 0.74 [ 0.62, 0.89 ]
Heterogeneity: Chi2 = 0.67, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.27 (P = 0.0011)
2 Hyperfractionated/accelerated versus conventional
Bourhis 2006 -0.4 (0.15) 8.7 % 0.67 [ 0.50, 0.90 ]
Dobrowsky 2000 -0.17 (0.19) 5.4 % 0.84 [ 0.58, 1.22 ]
Marcial 1987 -0.02 (0.16) 7.7 % 0.98 [ 0.72, 1.34 ]
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
(Continued . . . )
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Poulsen 2001 -0.07 (0.15) 8.7 % 0.93 [ 0.69, 1.25 ]
Subtotal (95% CI) 30.5 % 0.84 [ 0.72, 0.99 ]
Heterogeneity: Chi2 = 3.67, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 2.11 (P = 0.034)
3 Hyperfractionated/accelerated/split versus conventional
Bartelink 2002 -0.43 (0.32) 1.9 % 0.65 [ 0.35, 1.22 ]
Fu 2000 -0.08 (0.12) 13.6 % 0.92 [ 0.73, 1.17 ]
Horiot 1997 -0.29 (0.14) 10.0 % 0.75 [ 0.57, 0.98 ]
Olmi 2003 0.08 (0.21) 4.4 % 1.08 [ 0.72, 1.63 ]
Subtotal (95% CI) 30.0 % 0.86 [ 0.74, 1.01 ]
Heterogeneity: Chi2 = 3.31, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.84 (P = 0.066)
4 Accelerated versus conventional
Skladowski 2006 -1.33 (0.32) 1.9 % 0.26 [ 0.14, 0.50 ]
Subtotal (95% CI) 1.9 % 0.26 [ 0.14, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.16 (P = 0.000032)
5 Accelerated/boost versus conventional
Fu 2000 -0.25 (0.12) 13.6 % 0.78 [ 0.62, 0.99 ]
Subtotal (95% CI) 13.6 % 0.78 [ 0.62, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
Total (95% CI) 100.0 % 0.80 [ 0.73, 0.87 ]
Heterogeneity: Chi2 = 21.59, df = 12 (P = 0.04); I2 =44%
Test for overall effect: Z = 5.12 (P < 0.00001)
Test for subgroup differences: Chi2 = 13.95, df = 4 (P = 0.01), I2 =71%
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
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Analysis 1.3. Comparison 1 Altered fractionation versus conventional radiotherapy, Outcome 3 Disease
free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy
Comparison: 1 Altered fractionation versus conventional radiotherapy
Outcome: 3 Disease free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hyperfractionated versus conventional
Fu 2000 -0.13 (0.1) 21.4 % 0.88 [ 0.72, 1.07 ]
Subtotal (95% CI) 21.4 % 0.88 [ 0.72, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 Hyperfractionated/accelerated versus conventional
Poulsen 2001 -0.14 (0.14) 10.9 % 0.87 [ 0.66, 1.14 ]
Subtotal (95% CI) 10.9 % 0.87 [ 0.66, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
3 Hyperfractionated/accelerated/split versus conventional
Fu 2000 -0.07 (0.1) 21.4 % 0.93 [ 0.77, 1.13 ]
Olmi 2003 0.41 (0.18) 6.6 % 1.51 [ 1.06, 2.14 ]
Subtotal (95% CI) 28.0 % 1.04 [ 0.88, 1.24 ]
Heterogeneity: Chi2 = 5.43, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.49 (P = 0.62)
4 Accelerated versus conventional
Skladowski 2006 -1.14 (0.26) 3.2 % 0.32 [ 0.19, 0.53 ]
Weissberg 1983 -0.02 (0.18) 6.6 % 0.98 [ 0.69, 1.39 ]
Subtotal (95% CI) 9.8 % 0.68 [ 0.51, 0.91 ]
Heterogeneity: Chi2 = 12.54, df = 1 (P = 0.00040); I2 =92%
Test for overall effect: Z = 2.59 (P = 0.0097)
5 Accelerated/boost versus conventional
Ang 2001 0.36 (0.31) 2.2 % 1.43 [ 0.78, 2.63 ]
Fu 2000 -0.15 (0.1) 21.4 % 0.86 [ 0.71, 1.05 ]
Ghoshal 2008 -0.62 (0.21) 4.9 % 0.54 [ 0.36, 0.81 ]
Sanguineti 2005 -0.48 (0.39) 1.4 % 0.62 [ 0.29, 1.33 ]
Subtotal (95% CI) 29.9 % 0.82 [ 0.69, 0.96 ]
Heterogeneity: Chi2 = 8.03, df = 3 (P = 0.05); I2 =63%
Test for overall effect: Z = 2.41 (P = 0.016)
Total (95% CI) 100.0 % 0.88 [ 0.80, 0.96 ]
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 33.62, df = 9 (P = 0.00010); I2 =73%
Test for overall effect: Z = 2.80 (P = 0.0052)
Test for subgroup differences: Chi2 = 7.61, df = 4 (P = 0.11), I2 =47%
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
Analysis 2.1. Comparison 2 Summary analyses for altered fractionation versus conventional radiotherapy,
Outcome 1 Total mortality.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy
Comparison: 2 Summary analyses for altered fractionation versus conventional radiotherapy
Outcome: 1 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Ang 2001 0.39 (0.26) 4.0 % 1.48 [ 0.89, 2.46 ]
Bartelink 2002 0.1 (0.32) 2.9 % 1.11 [ 0.59, 2.07 ]
Bourhis 2006 -0.2 (0.14) 7.8 % 0.82 [ 0.62, 1.08 ]
Dobrowsky 2000 -0.1 (0.18) 6.2 % 0.90 [ 0.64, 1.29 ]
Fu 2000 -0.17 (0.1) 9.6 % 0.84 [ 0.69, 1.03 ]
Fu 2000 -0.09 (0.1) 9.6 % 0.91 [ 0.75, 1.11 ]
Fu 2000 0.01 (0.1) 9.6 % 1.01 [ 0.83, 1.23 ]
Horiot 1992 -0.27 (0.12) 8.6 % 0.76 [ 0.60, 0.97 ]
Horiot 1997 -0.02 (0.11) 9.1 % 0.98 [ 0.79, 1.22 ]
Marcial 1987 -0.07 (0.15) 7.3 % 0.93 [ 0.69, 1.25 ]
Olmi 2003 0.2 (0.2) 5.5 % 1.22 [ 0.83, 1.81 ]
Pinto 1991 -0.56 (0.22) 4.9 % 0.57 [ 0.37, 0.88 ]
Poulsen 2001 -0.18 (0.14) 7.8 % 0.84 [ 0.63, 1.10 ]
Sanguineti 2005 -0.29 (0.28) 3.6 % 0.75 [ 0.43, 1.30 ]
Skladowski 2006 -1.31 (0.28) 3.6 % 0.27 [ 0.16, 0.47 ]
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 100.0 % 0.86 [ 0.76, 0.98 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 34.34, df = 14 (P = 0.002); I2 =59%
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
Analysis 2.2. Comparison 2 Summary analyses for altered fractionation versus conventional radiotherapy,
Outcome 2 Locoregional control.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy
Comparison: 2 Summary analyses for altered fractionation versus conventional radiotherapy
Outcome: 2 Locoregional control
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Bartelink 2002 -0.43 (0.32) 3.2 % 0.65 [ 0.35, 1.22 ]
Bourhis 2006 -0.4 (0.15) 9.0 % 0.67 [ 0.50, 0.90 ]
Dobrowsky 2000 -0.17 (0.19) 6.8 % 0.84 [ 0.58, 1.22 ]
Fu 2000 -0.25 (0.12) 11.0 % 0.78 [ 0.62, 0.99 ]
Fu 2000 -0.08 (0.12) 11.0 % 0.92 [ 0.73, 1.17 ]
Fu 2000 -0.25 (0.12) 11.0 % 0.78 [ 0.62, 0.99 ]
Horiot 1992 -0.39 (0.15) 9.0 % 0.68 [ 0.50, 0.91 ]
Horiot 1997 -0.29 (0.14) 9.6 % 0.75 [ 0.57, 0.98 ]
Marcial 1987 -0.02 (0.16) 8.4 % 0.98 [ 0.72, 1.34 ]
Olmi 2003 0.08 (0.21) 6.0 % 1.08 [ 0.72, 1.63 ]
Pinto 1991 -0.17 (0.35) 2.7 % 0.84 [ 0.42, 1.68 ]
Poulsen 2001 -0.07 (0.15) 9.0 % 0.93 [ 0.69, 1.25 ]
Skladowski 2006 -1.33 (0.32) 3.2 % 0.26 [ 0.14, 0.50 ]
Total (95% CI) 100.0 % 0.79 [ 0.70, 0.89 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 21.59, df = 12 (P = 0.04); I2 =44%
Test for overall effect: Z = 3.81 (P = 0.00014)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
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Analysis 2.3. Comparison 2 Summary analyses for altered fractionation versus conventional radiotherapy,
Outcome 3 Disease free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy
Comparison: 2 Summary analyses for altered fractionation versus conventional radiotherapy
Outcome: 3 Disease free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Ang 2001 0.36 (0.31) 6.2 % 1.43 [ 0.78, 2.63 ]
Fu 2000 -0.07 (0.1) 13.4 % 0.93 [ 0.77, 1.13 ]
Fu 2000 -0.15 (0.1) 13.4 % 0.86 [ 0.71, 1.05 ]
Fu 2000 -0.13 (0.1) 13.4 % 0.88 [ 0.72, 1.07 ]
Ghoshal 2008 -0.62 (0.21) 9.1 % 0.54 [ 0.36, 0.81 ]
Olmi 2003 0.41 (0.18) 10.3 % 1.51 [ 1.06, 2.14 ]
Poulsen 2001 -0.14 (0.14) 11.9 % 0.87 [ 0.66, 1.14 ]
Sanguineti 2005 -0.48 (0.39) 4.6 % 0.62 [ 0.29, 1.33 ]
Skladowski 2006 -1.14 (0.26) 7.5 % 0.32 [ 0.19, 0.53 ]
Weissberg 1983 -0.02 (0.18) 10.3 % 0.98 [ 0.69, 1.39 ]
Total (95% CI) 100.0 % 0.85 [ 0.70, 1.03 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 33.62, df = 9 (P = 0.00010); I2 =73%
Test for overall effect: Z = 1.67 (P = 0.094)
0.1 0.2 0.5 1 2 5 10
Favours altered fraction Favours conventional
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Analysis 3.1. Comparison 3 Neutron therapy, Outcome 1 Total mortality.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy
Comparison: 3 Neutron therapy
Outcome: 1 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mixed beam (neutron/photon) versus photon
Griffin 1989 0.11 (0.1) 51.6 % 1.12 [ 0.92, 1.36 ]
Subtotal (95% CI) 51.6 % 1.12 [ 0.92, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Neutron versus photon
Griffin 1984 0.11 (0.38) 3.6 % 1.12 [ 0.53, 2.35 ]
Maor 1986 0.18 (0.19) 14.3 % 1.20 [ 0.82, 1.74 ]
Maor 1995 0.05 (0.13) 30.5 % 1.05 [ 0.81, 1.36 ]
Subtotal (95% CI) 48.4 % 1.10 [ 0.90, 1.34 ]
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 100.0 % 1.11 [ 0.96, 1.27 ]
Heterogeneity: Chi2 = 0.34, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.90), I2 =0.0%
0.2 0.5 1 2 5
Favours neutron Favours photon
A D D I T I O N A L T A B L E S
Table 1. Percentage of patients with oral cavity (OC) or oropharyngeal (OP) cancer in studies included in this review
Trial ID %OC %OP Total % OC/OP
Ang 2001* 49 51 100
Bergermann 1992 100 0 100
Horiot 1992 0 100 100
Inoue 2001 100 0 100
Marcial 1993 0 100 100
Olmi 2003 0 100 100
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Table 1. Percentage of patients with oral cavity (OC) or oropharyngeal (OP) cancer in studies included in this review
(Continued)
Pinto 1991 0 100 100
Sanguineti 2005* 100
Bourhis 2006 14 77 91
Bartelink 2002 33 47 80
Horiot 1997 16 64 80
Griffin 1989 27 52 79
Poulsen 2001 11 67 78
Maor 1986 26 51 77
Maor 1995 23 51 75
Hukku 1991 10 62 72
Dobrowsky 2000 30 41 71
Fu 2000 10 60 71
Lawrence 1974 45 26 71
Terz 1981 38 29 67
Ghoshal 2008 0 65 65
Cox 1990 20 44 64
Weissberg 1983 19 45 64
Fu 1995 11 51 61
MacDougall 1990 40 21 61
Marcial 1987 15 46 61
Griffin 1984 25 33 58
Ketcham 1969 56 unclear >56
Bjarnason 2009 19 35 54
Skladowski 2006 22 28 50
*Data were available from the authors for those participants with cancer of the oral cavity or oropharynx only.
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Table 2. Results from comparisons where there are data from a single study only
Total mortality Locoregional control Disease free survival
Accelerated/split versus conventional
Marcial 1993 5 years
RR 1.17 (95% CI 0.57 to
2.43)
Split course versus accelerated
Hukku 1991 2 years
RR 1.00 (95% CI 0.82 to 1.22)
2 years
RR 1.33 (95% CI 0.67 to
2.67)
2 years
RR 0.83 (95% CI 0.29 to
2.42)
Variable total dose/duration of radiotherapy
Cox 1990 High versus standard
HR 1.08 (95% CI 0.69 to
1.70)
High versus standard
HR 0.78 (95% CI 0.55 to 1.11)
Low versus standard
HR 1.38 (95% CI 0.83 to
2.29)
Low versus standard
HR 1.13 (95% CI 0.78 to 1.64)
Morning versus afternoon radiotherapy
Bjarnason 2009 2 years
RR 1.09 (95% CI 0.74 to
1.59)
HR 0.92 (95% CI 0.60 to 1.42)
Mixed beam versus photon
Griffin 1989 HR 1.12 (95% CI 0.92 to
1.36)
HR 1.04 (95% CI 0.84 to 1.29)
Neutron versus photon
MacDougall 1990 5 years
RR 1.15 (95% CI 0.95 to
1.40)
5 years
RR 0.97 (95% CI 0.69 to 1.36)
5 years
RR 0.63 (95% CI 0.36 to
1.09)
Pre-operative radiotherapy versus surgery alone
Ketcham 1969 Timing unclear
RR 0.63 (95% CI 0.28 to 1.46)
Terz 1981 HR 0.83 (95% CI 0.64 to
1.07)
89Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Results from comparisons where there are data from a single study only (Continued)
Pre-operative and post-operative radiotherapy versus post-operative radiotherapy alone
Bergermann 1992 HR 0.67 (95% CI 0.35 to
1.28)
HR 1.13 (95% CI 0.78 to 1.64) HR 1.13 (95% CI 0.78 to
1.64)
Low dose rate interstitial radiotherapy versus high dose rate interstitial radiotherapy
Inoue 2001 HR 1.00 (95% CI 0.16 to 6.44)
CI = confidence interval; HR = hazard ratio; RR = risk ratio.
Table 3. Sensitivity analyses: altered fractionation versus conventional radiotherapy
All trials Trials assessed as being at low risk of bias
Total mortality HR 0.86 (95% CI 0.76 to 0.98)
(13 trials)
HR 0.93 (95% CI 0.80 to 1.07)
(5 trials)
Locoregional control HR 0.79 (95% CI 0.70 to 0.89)
(11 trials)
HR 0.79 (95% CI 0.68 to 0.91)
(4 trials)
Disease free survival HR 0.85 (95% CI 0.70 to 1.03)
(8 trials)
HR 0.95 (95% CI 0.0.74 to 1.22)*
(2 trials)
*Fixed-effect model due to limited number of trials.
CI = confidence interval; HR = hazard ratio.
A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE via OVID
1. ”Head and Neck Neoplasms“/
2. ”Mouth Neoplasms“/
3. ”Gingival Neoplasms“/
4. ”Palatal Neoplasms“/
5. ”Tongue Neoplasms“/
6. ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or
intraoral$ or ”intra oral$“ or gingiva$ or oropharyn$ or mouth$ or tongue$ or cheek$ or gum$ or palatal$ or palate$ or ”head and
neck“)).mp.
7. or/1-6
8. exp Radiotherapy/
9. (radiotherap$ or chemotherap$ or chemoradiotherap$ or chemo-radiotherap$ or ”radiation therap$“ or bracytherap$ or
irradiat$).ti,ab.
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10. (adjuvant or neo-adjuvant or ”neo adjuvant“).ti,ab.
11. (hyperfractionate$ or hyper-fractionate$).mp.
12. exp Surgical Procedures, Operative/
13. (dissect$ adj2 neck$).ti,ab.
14. (excision or excise or resect$).ti,ab.
15. Lymph Node Excision/
16. (lymphadenectom$ or glossectom$).ti,ab.
17. exp Antineoplastic agents/
18. (antineoplast$ or antitumor$ or anti-tumor$ or anti-neoplast$ or antitumour$ or anti-tumour$).mp.
19. Antineoplastic combined chemotherapy protocols/
20. exp Combined Modality Therapy/
21. or/8-20
22. 7 and 21
The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in
MEDLINE: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the Cochrane
Handbook for Systematic Reviews of Interventions, version 5.0.2 (updated September 2009):
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 2. Cochrane Oral Health Group’s Trials Register search strategy
((mouth or oral or intraoral or intra-oral or gingiva* or oropharyn* or cheek* or gum* or palat* or lip or tongue or “head and neck”)
AND (tumour* or tumor* or cancer* or carcinoma* or neoplas* or malignan*))
Appendix 3. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
#1 MeSH descriptor Head and Neck Neoplasms this term only
#2 MeSH descriptor Mouth neoplasms this term only
#3 MeSH descriptor Gingival Neoplasms this term only
#4 MeSH descriptor Palatal neoplasms this term only
#5 MeSH descriptor Tongue neoplasms this term only
#6 ((cancer* near/5 oral*) or (cancer* near/5 intra-oral*) or (cancer* near/5 intraoral*) or (cancer* near/5 “intra) and oral”*) or
(cancer* near/5 gingiva*) or (cancer* near/5 oropharyn*) or (cancer* near/5 mouth*) or (cancer* near/5 tongue*) or (cancer* near/5
cheek*) or (cancer* near/5 gum*) or (cancer* near/5 palatal*) or (cancer* near/5 palate*) or (cancer* near/5 ”head and neck“))
#7 ((tumour* near/5 oral*) or (tumour* near/5 intra-oral*) or (tumour* near/5 intraoral*) or (tumour* near/5 “intra) and oral”*)
or (tumour* near/5 gingiva*) or (tumour* near/5 oropharyn*) or (tumour* near/5 mouth*) or (tumour* near/5 tongue*) or (tumour*
near/5 cheek*) or (tumour* near/5 gum*) or (tumour* near/5 palatal*) or (tumour* near/5 palate*) or (tumour* near/5 ”head and
neck“))
#8 ((tumor* near/5 oral*) or (tumor* near/5 intra-oral*) or (tumor* near/5 intraoral*) or (tumor* near/5 “intra) and oral”*) or
(tumor* near/5 gingiva*) or (tumor* near/5 oropharyn*) or (tumor* near/5 mouth*) or (tumor* near/5 tongue*) or (tumor* near/5
cheek*) or (tumor* near/5 gum*) or (tumor* near/5 palatal*) or (tumor* near/5 palate*) or (tumor* near/5 ”head and neck“))
#9 ((neoplas* near/5 oral*) or (neoplas* near/5 intra-oral*) or (neoplas* near/5 intraoral*) or (neoplas* near/5 “intra) and oral”*)
or (neoplas* near/5 gingiva*) or (neoplas* near/5 oropharyn*) or (neoplas* near/5 mouth*) or (neoplas* near/5 tongue*) or (neoplas*
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near/5 cheek*) or (neoplas* near/5 gum*) or (neoplas* near/5 palatal*) or (neoplas* near/5 palate*) or (neoplas* near/5 ”head and
neck“))
#10 ((malignan* near/5 oral*) or (malignan* near/5 intra-oral*) or (malignan* near/5 intraoral*) or (malignan* near/5 “intra) and
oral”*) or (malignan* near/5 gingiva*) or (malignan* near/5 oropharyn*) or (malignan* near/5 mouth*) or (malignan* near/5 tongue*)
or (malignan* near/5 cheek*) or (malignan* near/5 gum*) or (malignan* near/5 palatal*) or (malignan* near/5 palate*) or (malignan*
near/5 ”head and neck“))
#11 ((carcinoma* near/5 oral*) or (carcinoma* near/5 intra-oral*) or (carcinoma* near/5 intraoral*) or (carcinoma* near/5 “intra)
and oral”*) or (carcinoma* near/5 gingiva*) or (carcinoma* near/5 oropharyn*) or (carcinoma* near/5 mouth*) or (carcinoma* near/5
tongue*) or (carcinoma* near/5 cheek*) or (carcinoma* near/5 gum*) or (carcinoma* near/5 palatal*) or (carcinoma* near/5 palate*)
or (carcinoma* near/5 ”head and neck“))
#12 ((metatasta* near/5 oral*) or (metatasta* near/5 intra-oral*) or (metatasta* near/5 intraoral*) or (metatasta* near/5 “intra) and
oral”*) or (metatasta* near/5 gingiva*) or (metatasta* near/5 oropharyn*) or (metatasta* near/5 mouth*) or (metatasta* near/5 tongue*)
or (metatasta* near/5 cheek*) or (metatasta* near/5 gum*) or (metatasta* near/5 palatal*) or (metatasta* near/5 palate*) or (metatasta*
near/5 ”head and neck“))
#13 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12)
#14 MeSH descriptor Radiotherapy explode all trees
#15 (radiotherap* or chemotherap* or chemoradiotherap* or chemo-radiotherap* or ”radiation therap*“ or bracytherap* or irradiat*)
#16 (adjuvant or neo-adjuvant or ”neo adjuvant”)
#17 (hyperfractionate* or hyper-fractionate*)
#18 MeSH descriptor Surgical Procedures, Operative explode all trees
#19 (dissect* near/2 neck*)
#20 (excision or excise* or resect*)
#21 MeSH descriptor Lymph node excision this term only
#22 (lymphadenectom* or glossectom*)
#23 MeSH descriptor Antineoplastic agents explode all trees
#24 (antineoplast* or antitumor* or anti-tumor* or anti-neoplast* or antitumour* or anti-tumour*)
#25 MeSH descriptor antineoplastic combined chemotherapy protocols this term only
#26 MeSH descriptor combined modality therapy explode all trees
#27 (#14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26)
#28 (#13 and #27)
Appendix 4. EMBASE via OVID search strategy
1. “Head and Neck Neoplasms”/
2. “Mouth Neoplasms”/
3. “Gingival Neoplasms”/
4. “Palatal Neoplasms”/
5. “Tongue Neoplasms”/
6. ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or
intraoral$ or “intra oral$” or gingiva$ or oropharyn$ or mouth$ or tongue$ or cheek$ or gum$ or palatal$ or palate$ or “head and
neck”)).mp.
7. or/1-6
8. exp Radiotherapy/
9. (radiotherap$ or chemotherap$ or chemoradiotherap$ or chemo-radiotherap$ or “radiation therap$” or bracytherap$ or
irradiat$).ti,ab.
10. (adjuvant or neo-adjuvant or “neo adjuvant”).ti,ab.
11. (hyperfractionate$ or hyper-fractionate$).mp.
12. exp Surgical Procedures, Operative/
13. (dissect$ adj2 neck$).ti,ab.
14. (excision or excise or resect$).ti,ab.
15. Lymph Node Excision/
16. (lymphadenectom$ or glossectom$).ti,ab.
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17. exp Antineoplastic agents/
18. (antineoplast$ or antitumor$ or anti-tumor$ or anti-neoplast$).mp.
19. Antineoplastic combined chemotherapy protocols/
20. exp Combined Modality Therapy/
21. or/8-20
22. 7 and 21
The above subject search was linked to the Cochrane Oral Health Group filter for EMBASE via OVID:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/
16. HUMAN/
17. 16 and 15
18. 15 not 17
19. 14 not 18
H I S T O R Y
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Review first published: Issue 12, 2010
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with SF and AMG
• Undertaking searches: AL
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• Organizing retrieval of papers: AMG, SF, SP
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• Appraising risk of bias: AMG, SF, Paul Brocklehurst (PB)
• Extracting data from papers: AMG, HW, SF, PB
• Writing to authors of papers for additional information: SP, SF
• Data management for the review: AMG, SF, HW, SP
• Entering data into RevMan: AMG, SF
• Analysis of data: AMG, SF, HW
• Interpretation of data: AMG, SF, HW, Kelvin KW Chan (KC)
• Writing the review: AMG, SF, HW, KC.
The CSROC Expert Panel comprises:
Bertrand Baujat, Gerry Humphris, Iain Hutchison, Jean-Pierre Pignon, Gerry Robertson, Simon Rogers, Jatin Shah, Nick Slevin, Phil
Sloan, David Soutar, Erich Sturgis, Jan Vermorken, Steve Wardell, Saman Warnakulasuriya, Keith Webster.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• School of Dentistry, The University of Manchester, UK.
• Cochrane Oral Health Group, UK.
• The University of Dundee, UK.
• The University of Glasgow, UK.
• Manchester Academic Health Sciences Centre (MAHSC) and NIHR Manchester Biomedical Research Centre, UK.
External sources
• National Institute of Health, National Institute of Dental & Craniofacial Research, USA.
• Central Manchester & Manchester Children’s University Hospitals NHS Trust, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Types of studies: As the primary outcome for this review is total mortality we have added a requirement that included studies have a
minimum of 6 months of follow-up of participants after the end of treatment.
Types of participants: We have only included studies where at least 50% of the participants have either oral cavity or oropharyngeal
cancer, or where data for the oral cavity and oropharyngeal patients only are available.
Types of interventions: The intervention under evaluation must be radiotherapy. Trials where all participants receive the same radio-
therapy regimen and are randomised to other treatments were excluded.
Types of outcomes: The protocol for this review stated that quality of life would be a primary outcome for this review. Quality of
life is an important outcome, for both patients with oral cavity and oropharyngeal cancers and their doctors. However, quality of life
is infrequently and inconsistently reported in trials which address a primary outcome of overall survival. Therefore we have opted to
transfer this outcome to the list of secondary outcomes to be considered in future updates of this review as appropriate.
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Search methods: The search strategy has been updated.
Quality assessment has been replaced by the new risk of bias tool.
Data synthesis has been updated. The primary outcome is total mortality expressed as a hazard ratio. A meta-analysis of individual
patient data (IPD) for altered fractionation versus conventional fractionation has previously been published (Bourhis 2006). For trials
included in the Bourhis meta-analysis, the IPDwere used instead of data presented in the published reports. For dichotomous outcomes,
the estimates of effect of an intervention were expressed as risk ratios together with 95% confidence intervals. Dichotomous data were
only used for primary outcomes where hazard ratios were unavailable or could not be calculated.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Mouth Neoplasms [mortality; ∗radiotherapy]; Oropharyngeal Neoplasms [mortality; ∗radiotherapy]; Radiotherapy [adverse effects;
methods]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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